About: acn

紐約, 2025年10月31日 - (亞太商訊 via SeaPRwire.com) - TruMerit 公司總裁兼首席執行官彼得·普雷佐西（Peter Preziosi）當選為聯合國諮商地位非政府組織會議（簡稱 CoNGO）主席。CoNGO | TruMerit聯合國諮商地位非政府組織會議，亦稱為 CoNGO，與 TruMeritCoNGO 是一個成立於 1948 年的國際非政府組織，其與聯合國的關係基於聯合國經濟及社會理事會（ECOSOC）授予的“全面諮商地位”（General Consultative Status）。該組織目前擁有來自世界各地的 525 個會員組織以及 106 個準會員。普雷佐西博士（Dr. Preziosi）於本週在第 28 屆 CoNGO 大會上當選為 2025—2029 任期主席。大會在紐約舉行，同時也有來自全球各地的組織以線上方式參會。他接替了自 2017 年起擔任 CoNGO 主席、並曾在 2007 至 2011 年間任職的聯合衛理公會總會社會與公共事務委員會駐聯合國首席代表利貝拉托·C·包蒂斯塔牧師博士（Rev. Dr. Liberato C. Bautista）。TruMerit 自 2018 年起成為 CoNGO 成員，並積極參與該組織事務，曾擔任 CoNGO 理事會秘書以及會員委員會主席。普雷佐西博士（Dr. Preziosi）是首位擔任 CoNGO 主席的註冊護士。他是一位非營利機構高管，自 2023 年初起領導 TruMerit（前稱 CGFNS International），這是一家致力於促進全球衛生工作者倫理流動與職業發展的衛生人力資源發展組織。此前，他曾就職於世界衛生組織（WHO），協助建立該機構的技術驅動型全球學習中心——世衛學院（WHO Academy）。前任主席包蒂斯塔牧師博士（Dr. Bautista）對普雷佐西博士的當選表示熱烈祝賀。他說：“普雷佐西博士在 TruMerit 與世衛組織的工作經驗，加上他對多邊主義的深切奉獻以及他在公民社會中的積極參與，為我們對 CoNGO 的未來帶來了信心。在這個公民社會的聲音與影響力對於塑造以人類尊嚴、人權及地球可持續性為核心的共同未來至關重要的時代，普雷佐西博士的領導力有望進一步強化 CoNGO 在聯合國體系內外，推動民主與公平參與的重要作用。”普雷佐西表示：“長期以來，CoNGO 一直是非政府組織的重要匯聚平台，是連接公民社會與聯合國之間的橋樑，也是包容性多邊主義的堅定倡導者——這一理念遺憾地正日益受到衝擊。”他進一步指出：“對此，我們應當堅持認為公民社會在聯合國的參與不是一種請求，而是一項原則——這一原則對確保多邊主義的合法性、有效性和倫理性至關重要，也因此對於實現可持續發展目標以及維護法治具有關鍵意義。”關於 CoNGO（聯合國諮商地位非政府組織會議）聯合國諮商地位非政府組織會議（Conference of Non-Governmental Organizations in Consultative Relationship with the United Nations，簡稱 CoNGO）是一個獨立的國際會員協會，成立於 1948 年——《世界人權宣言》發表的同一年。作為具有聯合國經濟及社會理事會（ECOSOC）全面諮商地位的非政府組織（NGO），CoNGO 的工作涉及整個聯合國體系，包括秘書處、各專門機構、條約機構、區域委員會、研究所、峰會及世界會議。CoNGO 全心全意支持《聯合國憲章》中所載的目標與價值觀，並積極倡導通過多邊主義來應對全球政治、環境、衛生及其他挑戰。近 30 個隸屬於 CoNGO 的實質委員會（即 NGO 委員會）在紐約、日內瓦、維也納及世界各地區運作，體現了 CoNGO 對聯合國體系使命的堅定支持。CoNGO 的成員涵蓋廣泛領域的非政府組織，這些組織不僅與聯合國保持諮商關係，也彼此合作，並與志同道合的利益相關方攜手共進。官方網站：ngocongo.org關於 TruMeritTruMerit 是全球領先的醫療人力發展機構。前身為 CGFNS International，該組織擁有近 50 年歷史，致力於協助護理人員與其他醫療工作者——以及負責發照與聘用的機構——在尋求在美國及其他國家執業許可時，驗證其教育背景、專業技能與實踐經驗，促進其職業流動性。作為 TruMerit，該機構的使命已擴展為建立符合全球快速變遷健康需求的人力資源能力。通過旗下的全球健康人力發展研究院（Global Health Workforce Development Institute），TruMerit 正在推動以實證為基礎的研究、思想領導與倡議，支持各項醫療人力發展方案，包括全球認可的執業標準與認證，藉此強化醫療工作者的職業發展途徑。聯絡資訊David St. Johndstjohn@trumerit.org來源: TruMerit Copyright 2025 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

- 國際金融中心一期全層佔地20,000平方呎，設有近300個工作站- 豪華貴賓室及精緻舒適的會員休息室，配備全方位服務咖啡吧- 德事商務中心香港第13個據點開幕，進一步鞏固品牌於高端靈活辦公空間的領導地位香港, 2025年10月31日 - (亚太商訊) - 亞洲高端靈活辦公空間服務商德事商務中心（The Executive Centre，簡稱TEC）欣然宣布，其全新據點於香港中環核心地段的標誌性地標—國際金融中心一期（One IFC）9樓隆重開幕。全新的高級服務式辦公室佔地近20,000平方呎，設有近300個工作站，標誌著TEC在香港開設第13個中心的重要里程碑。這個全新據點展現了獨特與奢華的完美結合，提供一系列高端設施，迎合現代專業人士多樣化的需求。中心設有私人辦公室、經理套房，以及專為高層商務會晤而設的豪華VIP貴賓室。此外，亦配備兩間設備完善的會議室，成就無縫協作。德事商務中心香港區負責人Jennifer So就此次盛大開幕表示:「自1994年紮根香港以來，我們一直致力於為亞太地區的高端靈活辦公空間樹立標杆。今天，值此我們31週年之際，慶祝全新國際金融中心一期中心的開幕，並再次重申我們對卓越的不懈追求。這不僅是一個全新據點，更是我們理念的完美詮釋——將低調奢華與靈活創新完美融合，為客戶在瞬息萬變的商業環境中締造獨特競爭優勢。我們的擴展印證了TEC對香港市場的堅定信心，以及支持這座活力都會和助力企業在港蓬勃發展的承諾。」全新的中心設有精心設計的會員休息廊，並配備一站式服務的咖啡吧，讓尊貴會員在品味時光中，將維多利亞港的璀璨全景盡收眼底。室內設計匠心獨運，靈動曲線天花板下設有大理石打造的禮賓接待區，以溫潤木質細節點綴，巧妙演繹現代美學，為會員締造溫暖且激發靈感的尊貴空間體驗。尊享設施亮點包括：- VIP室配備名師設計家具及精緻裝潢，散發低調雅緻氣息- 兩間配備頂級科技及強效隔音設施的會議室，營造極致私隱與專注空間- 超過2,000平方呎的社交空間，設計風格優雅大方，適合舉辦企業活動及社交聚會- 設有哺乳室並配備按摩椅， 體貼滿足在職父母的需要TEC於國際金融中心一期的全新服務式辦公室，致力提供高級靈活辦公空間，為會員提供激發生產力與創意的環境。隨著國際金融中心一期新據點開幕，TEC持續拓展在香港的業務版圖，進一步鞏固作為靈活辦公空間行業先驅的地位，為尊貴會員締造無與倫比的專業辦公體驗。德事商務中心簡介德事商務中心為亞洲高級服務式辦公室專家，在1994 年於香港創立，至今在15 個國家和地區的37 個城市設有超過240 家商務中心。德事商務中心專為專業人士和業界領袖服務。德事商務中心為企業塑造成功而龐大的全球社區網絡，橫跨大中華地區、東南亞、北亞、印度、斯里蘭卡、中東和澳洲。我們每所中心都位於優越的地段，辦公空間設施一應俱全，迎合會員所需。由私人擁有的德事商務中心總部設於香港，提供優質的私人專屬和共享辦公空間、商務行政服務和會議設施，滿足各個業務所需。了解更多詳情，請瀏覽 www.executivecentre.com傳媒垂詢德事商務中心Pebble LeePebble_lee@executivecentre.com / +852 3951 9888 Copyright 2025 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

- Expansive 20,000 square feet centre featuring nearly 300 workstations in the prestigious One IFC.- Luxurious VIP Lounge and designer Members’ Lounge complemented by a fully serviced Barista Bar.- TEC's 13th centre in Hong Kong, reinforcing its leadership in premium flexible workspace solutions.HONG KONG, Oct 31, 2025 - (ACN Newswire via SeaPRwire.com) – The Executive Centre (TEC), a premium flexible workspace provider, is proud to announce the grand opening of its latest centre at Level 9, One IFC, an iconic address in the heart of Central Hong Kong. This new centre spans nearly 20,000 square feet and accommodates close to 300 workstations, marking a significant milestone as TEC’s 13th centre in the city.This new location epitomizes exclusivity and sophistication, offering a range of high-end amenities tailored to meet the diverse needs of modern professionals. Among its offerings are premium Private Offices, Manager Suites, and an exclusive luxury VIP Lounge designed for high-level meetings, complemented by two additional Meeting Rooms equipped with cutting-edge technology to facilitate seamless collaboration.Jennifer So, City Head of Hong Kong at The Executive Centre, remarked on the importance of this launch: “Since our inception in Hong Kong in 1994, we have strived to set the standard for premium flexible workspaces across Asia. Today, as we celebrate the opening of our new centre at One IFC during our 31st anniversary, we reaffirm our unwavering commitment to excellence. This centre is not merely a new location; it embodies our belief that a harmonious blend of luxury and flexibility is essential for providing our clients with a competitive edge in an ever-evolving business landscape. Our expansion here reflects our confidence in the Hong Kong market and our commitment to supporting businesses in this vibrant city.”The centre features a meticulously designed Members’ Lounge that boasts breathtaking panoramic views of Victoria Harbour, along with a fully serviced Barista Bar. The interior design, characterized by curve-inspired ceilings, a contemporary marble reception, and warm wooden accents, creates an inviting and inspiring atmosphere for all members.Additional highlights include:- A luxurious VIP Lounge that exudes a sense of ‘quiet luxury’ with designer furnishings and exquisite finishes.- Two contemporary Meeting Rooms equipped with cutting-edge technology and exceptional soundproofing for privacy and focus.- Over 2,000 square feet of elegantly appointed Event Space, ideal for hosting corporate events and networking functions.- A thoughtfully designed nursing room featuring a massage chair, catering to the needs of working parents.The Executive Centre at One IFC stands as a testament to TEC’s dedication to delivering best-in-class service and innovative workspace solutions, ensuring that members have access to an environment that fosters productivity and creativity.As TEC continues to expand its footprint in Hong Kong, the opening of this new centre at One IFC reinforces its position as a pioneer in the flexible workspace sector, committed to enhancing the professional experience for all its members.About The Executive CentreThe Executive Centre (TEC) is a premium flexible workspace provider, opened its doors in Hong Kong in 1994 and has over 240+ Centres in 37 cities and 15 markets.The Executive Centre caters to professionals and industry leaders. TEC has a global network spanning Greater China, Southeast Asia, North Asia, India, Sri Lanka, the Middle East, and Australia. Each Executive Centre offers a prestigious address with the advanced infrastructure to meet the needs of its Members.Privately owned and headquartered in Hong Kong, TEC provides Private and Shared Workspaces, Business Services, and Meeting & Events facilities to suit its clients’ business' needs.www.executivecentre.comPress EnquiriesThe Executive CentrePebble LeePebble_lee@executivecentre.com / +852 3951 9888 Copyright 2025 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

Vancouver, British Columbia--(ACN Newswire via SeaPRwire.com - October 30, 2025) - Doubleview Gold Corp. (TSXV: DBG) (OTCQB: DBLVF) (FSE: 1D4) (the "Company" or "Doubleview") is pleased to announce a non-brokered private placement of flow-through shares and non-flow-through units for gross proceeds of up to C$10,000,000 (the "Private Placement"). Proceeds of the Private Placement shall be used to fund the current exploration program and general working capital. Proceeds of the sale of the FT Shares will be used for exploration work on its BC projects, particularly for the polymetallic Hat Project, located in northwestern BC. This work includes drilling, geological advisory and analytical services as well as other development work and other "Canadian exploration expenses" that qualify as "flow-through mining expenditures" (as such terms are defined in the Income Tax Act (Canada) (the "Tax Act")).The flow-through portion of the Private Placement will consist of up to 5,000,000 flow-through Shares ("FT shares ") at a price of $1.00 per FT share for up to C$5,000,000.Additionally, the Company will issue up to 7,142,857 hard dollar units ("non-FT Units") at a price of $0.70 per non-FT Unit, for up to C$5,000,000. Each non-FT Unit will consist of one common share and one full Warrant at an exercise price of $1.00 for 24 months from the date of issue. Each Warrant shall be subject to an accelerated expiry date at the option of the Company in the event the ten (10) day volume-weighted average price of the common shares of the Company on the TSXV for any ten (10) consecutive trading days is $1.25 or more.Pursuant to applicable Canadian securities laws and in accordance with the TSX Venture Exchange policies, all securities issued under this Offering will be subject to applicable resale restrictions under applicable securities laws and to the Exchange hold period of four-months and one day from the date of issuance. In connection with the Private placement, Doubleview may pay a finder's fees in accordance with the policies of the TSXV consisting of cash and/or finder's shares.The closing of the Offering is subject to receipt of all necessary regulatory approvals including the TSX Venture ExchangeAbout Doubleview Gold CorpA mineral resource exploration and development company is headquartered in Vancouver, British Columbia, Canada. It is publicly traded on the TSX Venture Exchange (TSXV: DBG) (OTCQB: DBLVF) (WKN: A1W038) and (FSE: 1D4). Doubleview focuses on identifying, acquiring, and financing precious and base metal exploration projects across North America, with a strong emphasis on British Columbia. The company enhances shareholder value through the acquisition and exploration of high-quality gold, copper, cobalt, scandium, and silver projects-collectively critical minerals-utilizing cutting-edge exploration techniques.Doubleview's success is deeply rooted in the unwavering support of its long-term shareholders, supporters, and institutional investors. Their ongoing commitment has been instrumental in advancing the company's strategic initiatives. Doubleview looks forward to further collaborative growth and development and continues to welcome active participation from its valued stakeholders as the company expands its portfolio and strengthens its position in the critical minerals sector.About the Hat Polymetallic DepositThe Hat Deposit, located in northwestern British Columbia, is a polymetallic porphyry project with major resources of copper, gold, cobalt, and the potential for scandium. As one of the region's significant sources of critical minerals, the Hat deposit has undergone targeted exploration and development. The 0.2% CuEq cut-off resource estimate, as of the recently completed Mineral Resource Estimate and the Company's July 25, 2024, news release, is summarized below:Open Pit Model HatResource CategoryTonnageAverage GradeMetal ContentCuEqCuCoAuAgCuEqCuCoAuAgMt%%%g/tg/tmillion lbmillion lbmillion lbthousand ozthousand ozIn PitIndicated1500.4080.2210.0080.190.421,353733289292,045Inferred4770.3440.1850.0090.150.493,6191,945912,3287,575 Scandium potential for the Hat Deposit is estimated to be 300 to 500 million tonnes at an average grade of 40 ppm (0.004%) Sc2O3.For further details, please refer to the Company's July 25, 2024 news release.Qualified Person:Erik Ostensoe, P. Geo., a consulting geologist, and Doubleview's Qualified Person with respect to the Hat Project as defined by National Instrument 43-101 Standards of Disclosure for Mineral Projects, has reviewed, and approved the written technical disclosure contained in the news release. He is not independent of Doubleview as he is a shareholder in the company.On behalf of the Board of Directors,Farshad Shirvani, President & Chief Executive OfficerFor further information please contact:Doubleview Gold CorpVancouver, BC Farshad ShirvaniPresident & CEOT: (604) 678-9587E: corporate@doubleview.caNEITHER TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICES PROVIDER (AS THAT TERM IS DEFINED IN THE POLICIES OF THE TSX VENTURE EXCHANGE) ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.The information contained herein contains "forward-looking information" and "forward-looking statements" within the meaning of applicable securities legislation (collectively, "forward-looking statements"). Forward-looking statements relate to information that is based on assumptions of management, forecasts of future results, and estimates of amounts not yet determinable. All statements, other than statements of historical fact, are forward-looking statements and are based on predictions, expectations, beliefs, plans, projections, objectives and assumptions made as of the date of this news release, including without limitation: the size of the Private Placement and other statements concerning the Private Placement; the anticipated use of proceeds from the Private Placement; the renunciation to the purchasers of FT Shares and timing thereof; the tax treatment of the FT Shares and the Company's plans regarding exploring its mineral exploration properties; anticipated results of geophysical drilling programs, geological interpretations and potential mineral recovery. Any statement that involves discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions, future events or performance (often but not always using phrases such as "expects", or "does not expect", "is expected", "anticipates" or "does not anticipate", "plans", "budget", "scheduled", "forecasts", "estimates", "believes" or "intends" or variations of such words and phrases or stating that certain actions, events or results "may" or "could", "would", "might" or "will" be taken to occur or be achieved) are not statements of historical fact and may be forward-looking statements.Forward-looking statements are subject to a variety of risks and uncertainties which could cause actual events or results to differ from those reflected in the forward-looking statements, including, without limitation: risks related to failure to obtain adequate funding on a timely basis and on acceptable terms; risks related to the outcome of legal proceedings; political and regulatory risks associated with mining and exploration; risks related to the maintenance of stock exchange listings; risks related to environmental regulation and liability; the potential for delays in exploration or development activities or the completion of feasibility studies; the uncertainty of profitability; risks and uncertainties relating to the interpretation of drill results, the geology, grade and continuity of mineral deposits; risks related to the inherent uncertainty of production and cost estimates and the potential for unexpected costs and expenses; results of prefeasibility and feasibility studies, and the possibility that future exploration, development or mining results will not be consistent with the Company's expectations; risks related to the gold price and other commodity price fluctuations; and other risks and uncertainties related to the Company's prospects, properties and business detailed elsewhere in the Company's disclosure record. Should one or more of these risks and uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described in forward-looking statements. Investors are cautioned against attributing undue certainty or reliance on forward-looking statements. These forward-looking statements are made as of the date hereof and the Company does not assume any obligation to update or revise any forward-looking statements, other than as required by applicable law, to reflect new information, events or circumstances, or changes in management's estimates, projections or opinions. Actual events or results could differ materially from those anticipated in the forward-looking statements or from the Company's expectations or projections.To view the source version of this press release, please visit https://www.newsfilecorp.com/release/272690 Copyright 2025 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

香港, 2025年10月31日 - (亞太商訊 via SeaPRwire.com) - 君聖泰醫藥（股票代碼：2511.HK），一家專注于開發多功能創新療法，以解決代謝性慢病未滿足臨床需求的創新藥公司，宣佈HTD1801在2型糖尿病（T2DM）患者中開展的兩項III期臨床試驗（SYMPHONY-1和SYMPHONY-2）已順利完成。在包含雙盲治療期和開放延長治療期（OLE）的52周研究中，HTD1801展現出長期持久的療效與良好的安全性。兩項III期臨床研究的52周数据充分驗證了HTD1801療效的持久性，並進一步凸顯其為T2DM患者帶來的長期綜合臨床獲益。君聖泰醫藥計畫於今年內向國家藥品監督管理局（NMPA）藥品審評中心（CDE）遞交HTD1801治療T2DM適應症的新藥上市申請（NDA）。SYMPHONY-1（NCT06350890）及SYMPHONY-2（NCT06353347）試驗是兩項隨機、雙盲、安慰劑對照的III期臨床試驗，旨在分別評估HTD1801在飲食及運動干預後血糖控制不佳（SYMPHONY-1；N=408）和二甲雙胍治療後血糖控制不佳（SYMPHONY-2；N=551）的T2DM成人受試者中的有效性和安全性。兩項研究的主要療效終點為：與安慰劑相比，HTD1801治療24周後糖化血紅蛋白（HbA1c）相對於基線的變化。隨後所有受試者進入為期28周的OLE期並接受HTD1801的治療。研究繼續評估了各療效終點在第52周時相對於基線變化，以進一步驗證HTD1801療效的持久性。降糖療效穩健持久：24周雙盲期療效得到長期維持，52周数据印證HTD1801帶來持久獲益SYMPHONY-1（單藥治療）：HTD1801治療組第24周HbA1c較基線平均變化值為-1.3%，顯著優於安慰劑組。持續接受HTD1801治療的患者在第52周時HbA1c的較基線降幅（-1.2%）維持穩定。由安慰劑轉至HTD1801治療的患者，在第52周時其HbA1c較基線的平均變化值為-1.3%，進一步驗證了雙盲期結果的可靠性。SYMPHONY-2（與二甲雙胍聯合治療）：HTD1801治療組第24周HbA1c較基線平均變化值為-1.2%，顯著優於安慰劑組。持續接受HTD1801治療的患者在第52周時HbA1c的較基線降幅（-1.1%）依然穩定。由安慰劑轉換至HTD1801治療的患者，在第52周時其HbA1c較基線的平均變化值為-1.2%，再次印證了雙盲期的研究結果。心腎代謝多重獲益：HTD1801對多項心腎代謝指標的改善在52周時均持續獲益兩項研究中，雙盲期HbA1c達標（HbA1c<7.0%）的患者比例在第52周時仍保持穩定。與此同時，HTD1801在降低血脂方面的療效亦長期穩定，包括低密度脂蛋白膽固醇（LDL-C）與非高密度脂蛋白膽固醇（non-HDL-C）均顯著下降。HTD1801長期治療還可持續降低與心血管事件及T2DM患者臨床結局密切相關的炎症標記物γ-谷氨酰轉移酶（GGT）和超敏C反應蛋白（hs-CRP）。值得關注的是，全體患者的估算腎小球濾過率（eGFR）在治療期間保持穩定。在合併輕度腎功能損害的患者中，第24周觀察到的eGFR改善在第52周時仍然保持，顯示HTD1801的腎臟保護潛力。相關数据將在近期學術會議公佈。良好的安全性與耐受性HTD1801在長期治療中展現出良好的安全性與耐受性，與雙盲期結果保持一致。對於接受HTD1801治療的患者，治療期延長不會增加其不良事件的類型與嚴重程度。該臨床試驗的主要研究者，前國際糖尿病聯盟（IDF）副主席、北京大學糖尿病中心主任、北京大學人民醫院內分泌和代謝科主任紀立農教授指出：“這兩項臨床試驗52周研究結果進一步表明，HTD1801有望成為T2DM患者差異化的創新治療選擇。HTD1801是全球首創的新分子實體，作為抗炎代謝調節劑（AIMM），具有啟動AMPK並抑制NLRP3炎性小體的雙重作用機制，與現有治療方案在機制上有很大的差異。其獨特藥理機制在臨床療效上表現出多重獲益：不僅能夠有效降糖，還可改善脂質代謝，抑制慢性代謝性炎症，並有改善腎功能的潛力。這一綜合療效使HTD1801有潛力成為心腎代謝系統疾病（CKM）的新治療藥物，有改善糖尿病及相關併發症的關鍵驅動因素的潛力，並和現有降糖藥物機制互補，能夠聯合使用。”君聖泰醫藥的創始人、董事長兼首席執行官劉利平博士表示：“我們向參與這幾項關鍵臨床研究的患者致以誠摯的謝意。對於T2DM這類慢性進展性疾病而言，療效的持久性是衡量長期治療成功的核心標準。HTD1801在代謝、炎症及腎功能等多個層面展現出的持久獲益，有助於降低微血管及大血管併發症的風險。我們期待即將公佈的與達格列淨頭對頭的III期研究結果，並將繼續挖掘HTD1801其它適應症的臨床潛力，為慢性代謝性疾病患者提供更綜合全面、且長期有效的治療方案。”關於2型糖尿病（T2DM）根據國際糖尿病聯盟（IDF）統計，2024年有5.89億成年人（20-79歲）患有糖尿病，預計到2050年將增至8.53億（即每8個成年人中就有1人患有糖尿病），其中90%為T2DM。中國是全球糖尿病患者人數最多的國家，2024年患者人數約為1.48億人，預計2050年將增至1.68億人。目前，糖尿病每年導致超過600萬人死亡，該疾病及其相關的一系列代謝問題，給社會和人民帶來了沉重的負擔。為應對這一急迫挑戰，臨床上急需為全球患者帶來綜合獲益的創新療法。關於HTD1801HTD1801是一款全球首創的新分子實體，旨在解決心腎代謝系統疾病（CKM）的未滿足臨床需求。HTD1801是口服抗炎及代謝調節劑（AIMM），作為單一分子具有獨特雙機制，通過啟動AMPK及抑制NLRP3炎症小體發揮其生物學活性；這種互補協同的雙機制作用可有效緩解代謝問題。全球多項臨床結果驗證HTD1801具有“一藥多效”的特性，能夠為患者帶來綜合獲益，包括改善胰島素敏感性、血糖控制、血脂降低、腎臟保護、體重減輕、肝臟獲益及抗炎等。基於此，HTD1801有潛力成為CKM領域的基礎性治療藥物。 Copyright 2025 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

HONG KONG, Oct 31, 2025 - (ACN Newswire via SeaPRwire.com) – HighTide Therapeutics, Inc. (2511.HK), a biopharmaceutical company specializing in the development of multifunctional, multi-targeted therapies for chronic metabolic diseases, announced positive 52-week safety and efficacy results from the open-label extension (OLE) phases of two Phase III trials (SYMPHONY-1 and SYMPHONY-2) evaluating HTD1801 in patients with type 2 diabetes mellitus (T2DM).The 52-week data from these two Phase III clinical trials demonstrate the durability of response and highlight the comprehensive long-term clinical benefits of HTD1801 in patients with T2DM. HighTide plans to submit a new drug application (NDA) for HTD1801 as a treatment for T2DM to the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) later this year.SYMPHONY-1 (NCT06350890) and SYMPHONY-2 (NCT06353347) are randomized, double-blind, placebo-controlled, Phase III clinical trials designed to evaluate the efficacy and safety of HTD1801 in adults with T2DM and inadequate glycemic control despite diet and exercise (SYMPHONY-1; N=408) or with Metformin (SYMPHONY-2; N=551). The primary endpoint in both studies was the change in glycated hemoglobin (HbA1c) from baseline with HTD1801 compared to placebo after 24 weeks of treatment. Patients were eligible to continue in a 28-week OLE during which all patients received HTD1801; Durability of response across efficacy endpoints was evaluated based on the change from baseline to Week 52.Efficacy observed during the 24-week double-blind period was durable and maintained with longer-term treatment through 52 weeks in both studiesSYMPHONY-1 (HTD1801 as monotherapy): At week 24, the reduction from baseline in HbA1c with HTD1801 (-1.3%) was superior to placebo. HbA1c reductions were maintained in patients who continued receiving HTD1801 (-1.2% at Week 52). Placebo patients who switched to HTD1801 saw a reduction in HbA1c of -1.3% at Week 52, substantiating the double-blind phase findings.SYMPHONY-2 (HTD1801 as an add-on therapy to Metformin): At week 24, the reduction from baseline in HbA1c with HTD1801 (-1.2%) was superior to placebo. HbA1c reductions were sustained in patients who continued receiving HTD1801 (-1.1% at Week 52). Placebo patients who switched to HTD1801 saw a reduction in HbA1c of -1.2% at Week 52, also substantiating the double-blind phase findings.In both studies, the durability of effect on other cardiometabolic and renal endpoints was maintained at 52 weeks, suggesting comprehensive advantages of HTD1801 beyond glycemic control with long-term treatment.In both studies, the proportion of patients receiving HTD1801 during the double-blind phase who achieved target HbA1c<7.0% was sustained through Week 52. The lipid-lowering effects observed during the double-blind phase, including significant reductions in low-density lipoprotein cholesterol (LDL-C) and non-high-density lipoprotein cholesterol (non-HDL-C), were also maintained. Long-term HTD1801 treatment also led to continued reductions in key inflammatory biomarkers, including gamma-glutamyl transferase (GGT) and high-sensitivity C-reactive protein (hs-CRP), both associated with cardiovascular risk in patients with T2DM.Notably, while estimated glomerular filtration rate (eGFR) remained stable in the overall population, the improvement of eGFR in patients with mild renal impairment at Week 24 was preserved at Week 52. These data highlighting the potential renal benefit of HTD1801 will be presented at a forthcoming scientific meeting.Favorable safety and tolerability profileOverall, long-term safety and tolerability were favorable and consistent with the double-blind phase. The types and severity of AEs did not increase with continued HTD1801 treatment compared to newly initiated HTD1801 treatment.“The robust 52-week results from these trials reinforce that HTD1801 may represent a novel and truly differentiated therapeutic option for patients with T2DM,” said Dr. Linong Ji, Lead Principal Investigator, former Vice President of the International Diabetes Federation (IDF), and Director of the Peking University Diabetes Center and the Department of Endocrinology and Metabolism at Peking University People’s Hospital. “As a first-in-class new molecular entity, HTD1801 is an anti-inflammatory metabolic modulator (AIMM) with a dual mechanism of action, AMP kinase activation and NLRP3 inflammasome inhibition, distinct from existing therapies. Its unique profile is designed not only to lower blood glucose, but also to improve lipid metabolism, exert anti-inflammatory effects, and potentially enhance renal function, supporting its potential as a backbone therapy to address the cardiovascular-kidney-metabolic (CKM) syndrome by targeting the underlying drivers of diabetes and diabetes-related complications. In addition, the unique mechanism allows for potential of combination treatments”“We extend our deepest gratitude to the patients who participated in these pivotal studies,” said Dr. Liping Liu, Founder, Chairperson, and CEO of HighTide Therapeutics. “Given the progressive nature of T2DM, durability of effect is a key determinant of long-term therapeutic success. The sustained beneficial effects of HTD1801 on metabolic, inflammatory, and renal parameters help reduce the risk of both microvascular and macrovascular complications. We look forward to sharing results from our Phase III head-to-head study with dapagliflozin, and will continue to explore HTD1801’s potential to deliver patients with chronic metabolic diseases a truly comprehensive, long-term treatment solution.”About Type 2 Diabetes Mellitus (T2DM)According to the International Diabetes Federation (IDF), 589 million adults (ages 20-79) were living with diabetes in 2024, and this number is projected to grow to 853 million (representing 1 in 8 adults) by 2050, of these, around 90% are T2DM cases. China has the largest population of diabetes patients worldwide, estimated to be 148 million in 2024, and projected to grow to 168 million in 2050. Diabetes is a global societal burden leading to over 6 million deaths per year. To address this urgent challenge, there is a critical need for innovative therapies that can deliver comprehensive clinical benefits for patients worldwide.About HTD1801HTD1801 is a first-in-class new molecular entity that targets the residual risks underlying cardiovascular–kidney–metabolic (CKM) diseases. It is an orally delivered, anti-inflammatory metabolic modulator (AIMM) that, as a single molecule, exerts a unique dual mechanism of action through activation of AMP Kinase and inhibition of the NLRP3 inflammasome, two complementary pathways that mitigate metabolic dysfunction. Multiple global clinical studies have demonstrated the comprehensive benefits of HTD1801, including improved insulin sensitivity, glycemic control, lipid lowering, renal protection, weight reduction, hepatic improvement, and anti-inflammatory effects. Collectively, these findings support the potential of HTD1801 to serve as a foundation therapy in CKM disease management. Copyright 2025 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

NEW YORK, Oct 31, 2025 - (ACN Newswire via SeaPRwire.com) - TruMerit President and CEO Peter Preziosi has been elected President of the Conference of Non-Governmental Organizations in Consultative Relationship with the United Nations, also known as CoNGO.CoNGO | TruMeritConference of Non-Governmental Organizations in Consultative Relationship with the United Nations, also known as CoNGO and TruMeritCoNGO is an international non-governmental organization founded in 1948 that relates to the United Nations through its General Consultative Status granted by the United Nations Economic and Social Council (ECOSOC). It has 525 member organizations from around the world and 106 associate members.Dr. Preziosi was elected to serve for the 2025-29 term this week at the 28th CoNGO General Assembly, which took place in New York with the virtual participation of organizations from around the world. He succeeds the Rev. Dr. Liberato C. Bautista, the main representative to the UN for the General Board of Church and Society of The United Methodist Church, who has served as CoNGO's President since 2017 and also held the post from 2007 to 2011.TruMerit has been a member of CoNGO since 2018 and is active in the organization's affairs, having served as the organization's Secretary to the CoNGO Board and as chair of its Membership Committee.Dr. Preziosi is the first Registered Nurse to serve as CoNGO President. He is a nonprofit executive who since early 2023 has led TruMerit, formerly known as CGFNS International, a health workforce development organization committed to advancing the ethical mobility and professional growth of health workers worldwide. Previously, he was employed by the World Health Organization to help establish its technology-driven global learning center, the WHO Academy.Dr. Bautista, the former President of CoNGO, extended his warm congratulations to Dr. Preziosi on his election. "His experience at TruMerit and at WHO, coupled with his profound dedication to multilateralism and his engagement with civil society, provide a basis for optimism regarding CoNGO's future. In an era where the voice and influence of civil society are of paramount importance in shaping a shared future that upholds human dignity and rights, as well as planetary sustainability, Dr. Preziosi's leadership is expected to enhance CoNGO's role as a pivotal supporter and advocate for democratic and equitable participation within the United Nations and beyond," he stated."CoNGO has long been a vital convener of NGOs, a bridge between civil society and an advocate for their engagement at the United Nations, as well as a steadfast champion of inclusive multilateralism - a concept that, unfortunately, is increasingly under attack," said Preziosi."In response, let us assert civil society participation at the United Nations not as a plea, but as a principle - one that is essential to legitimate, effective, and ethical multilateralism, and thereby is critical to the attainment of the Sustainable Development Goals and adherence to the rule of law," he said.About CoNGO (Conference of Non-Governmental Organizations in Consultative Relationship with the United Nations)The Conference of Non-Governmental Organizations in Consultative Relationship with the United Nations (CoNGO) is an independent, international membership association founded in 1948, the year of the Universal Declaration of Human Rights. As a non-governmental organization (NGO) in general consultative status with the UN Economic and Social Council, our work relates to the entire United Nations System: the Secretariat, Agencies, Treaty Bodies, Regional Commissions, Institutes, Summits and World Conferences.CoNGO wholeheartedly endorses the goals and values enshrined in the United Nations Charter and is a strong advocate for multilateralism to resolve global political, environmental, health, and other threats. Close to 30 CoNGO Substantive Committees (called NGO Committees) related to CoNGO in New York, Geneva, Vienna, and regions worldwide demonstrate our commitment to supporting the mission of the United Nations, systemwide. CoNGO has a membership of diverse NGOs working in consultation with the United Nations, in collaboration with each other, and in cooperation with other like-minded stakeholders. ngocongo.orgAbout TruMeritTruMerit is a worldwide leader in healthcare workforce development. Formerly known as CGFNS International, the organization has a nearly 50-year history supporting the career mobility of nurses and other healthcare workers - and those who license and hire them - by validating their education, skills, and experience as they seek authorization to practice in the United States and other countries. As TruMerit, this mission has been expanded to building workforce capacity that meets the needs of people in a rapidly evolving global health landscape. Through its Global Health Workforce Development Institute, the organization is advancing evidence-based research, thought leadership, and advocacy in support of healthcare workforce development solutions, including globally recognized practice standards and certifications that will enhance career pathways for healthcare workers. www.trumerit.orgContact InformationDavid St. Johndstjohn@trumerit.orgSOURCE: TruMerit Copyright 2025 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

Auckland, New Zealand, Oct 30, 2025 - (ACN Newswire via SeaPRwire.com) - At the inaugural European Union – New Zealand Business Summit, Decent Cybersecurity represented Europe's growing strength in digital and defence technologies. The company's Founder and CEO, Matej Michalko, joined industry leaders to discuss innovation partnerships, cybersecurity resilience, and post-quantum readiness across trans-Pacific markets. The event gathered over 400 participants from business, technology, and research communities, underscoring a shared commitment to building secure and sustainable digital infrastructure between Europe and New Zealand.Hosted by Hon Todd McClay, New Zealand's Minister for Trade & Investment, in partnership with Team Europe (the Ambassadors of the EU and its Member States), the Summit celebrated the strong growth of trans-Pacific cooperation. Since the EU–NZ Free Trade Agreement entered into force in 2024, two-way trade has already risen by NZ $2 billion, reaching NZ $21.6 billion in 2025.The event was officially opened by Prime Minister Christopher Luxon, who described the EU as "an innovation partner" and emphasised the shared values and strategic alignment between Europe and New Zealand in advancing trade, defence, and technology.A Platform for Global Partnerships and Digital InnovationCommissioner Šefcovic, a native of Slovakia, delivered a keynote address outlining Europe's vision for resilient supply chains, strategic autonomy, and secure digital transition. Later in the day, the "Quickfire with Central and Eastern Europe" session showcased innovation leaders from across the region.Representing European Union and its member country Slovakia, Matej Michalko presented on the country's growing role in post-quantum cybersecurity, AI for defence systems, and trusted blockchain infrastructure — areas where Decent Cybersecurity is establishing Europe-wide leadership."It was an honour to represent European Union and Slovakia alongside Commissioner Šefcovic and to demonstrate how our country is contributing to Europe's digital and defence sovereignty," said Matej Michalko, CEO of Decent Cybersecurity. "The EU–New Zealand partnership opens new doors for innovation, technology exchange, and secure infrastructure development that transcend continents."Shared Vision for Innovation and SecurityThe Summit agenda featured strategic panels on clean tech, AI, bioeconomy, and aerospace & defence, with global leaders from Airbus, Rocket Lab, OHB, and Maersk. It culminated with a joint address by Commissioner Šefcovic and Minister McClay, setting out a shared vision for deeper economic and technological integration between Europe and New Zealand — an effort strongly endorsed by Prime Minister Luxon in his opening remarks.For Decent Cybersecurity, participation in this summit reinforces its mission to connect European post-quantum, blockchain and AI-driven innovation with global partners in the Asia-Pacific region — bridging defence, technology, and critical-infrastructure ecosystems.About Decent CybersecurityDecent Cybersecurity s. r. o. is a European deep-tech company developing post-quantum and blockchain-based cybersecurity solutions for defence and critical infrastructure. Certified by TÜV SÜD (ISO 9001 and ISO 27001) and holding NATO, EU, and national SECRET-level security clearances, the company is a member of European Defence Fund (EDF) projects and a founding member of the Critical Infrastructure Association of Slovak Republic (Asociácia kritickej infraštruktúry SR, AKI SR).Media contactBrand: Decent CybersecurityContact: Media teamWebsite: https://decentcybersecurity.eu Copyright 2025 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

SHENZHEN, Oct 30, 2025 - (ACN Newswire via SeaPRwire.com) - China Medical System Holdings Limited (“CMS”) is pleased to announce that its subsidiary, Dermavon Holdings Limited (“Dermavon”, an innovative pharmaceutical company specialized in skin health which is applying for a separate listing on the Main Board of The Stock Exchange of Hong Kong Limited, please refer to the announcement of CMS on 22 April 2025 for details) together with its subsidiaries, holds co-development rights (except for atopic dermatitis (AD)) and exclusive commercialization rights for the Class 1 innovative drug anti-IL-4Rα MG-K10 humanized monoclonal antibody injection (“MG-K10” or the “Product”). The New Drug Application (“NDA”) has been accepted by National Medical Products Administration (“NMPA”) on 30 October 2025. The product is intended for the treatment of adult with moderate-to-severe AD whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable.MG-K10 (generic name: Comekibart Injection) is an innovative long-acting anti-IL-4Rα humanized monoclonal antibody that simultaneously blocks the signaling of key type 2 inflammatory cytokines IL-4 and IL-13. With a longer half-life, the Product enables a four-week dosing frequency (currently marketed anti-IL-4Rα drugs require biweekly dosing), which is expected to improve patient adherence. MG-K10 is expected to become the world's first long-acting anti-IL-4Rα monoclonal antibody to be launched on the market, and has the potential to become the Best-in-Class (BIC).MG-K10 has achieved positive results in a randomized, double-blind, placebo-controlled Phase III clinical study in adults with moderate-to-severe AD, meeting the primary research endpoint as designed, and at 52 weeks of treatment with MG-K10, proportion of participants with Investigator Global Assessment (IGA) score of 0 or 1, also with an improvement of ≥2 points from baseline is 76.6%; proportion of participants with ≥75% reduction in Eczema Area and Severity Index (EASI 75) from baseline is 94.3 %; proportion of participants with ≥90% reduction in Eczema Area and Severity Index (EASI 90) from baseline is 79.1 %. Regarding safety, most of the Treatment Emergent Adverse Event (TEAE) were Grade 1-2, with no Adverse Event of Special Interest (AESI) or fatal adverse event occurred. The incidence of common adverse reactions (conjunctivitis, injection site reactions, etc.) of drugs with the same target is relatively low for MG-K10.The Product has the potential for the treatment of other type 2 inflammatory diseases, such as asthma, prurigo nodularis, seasonal allergic rhinitis, chronic obstructive pulmonary disease, chronic spontaneous urticaria, chronic rhinosinusitis with nasal polyps, and eosinophilic esophagitis. Among them, asthma, prurigo nodularis and seasonal allergic rhinitis have all entered the phase III clinical trial stage in China.If MG-K10 is approved, it will provide a new, effective, and safe systemic treatment option for 14.5 million patients with moderate-to-severe AD[1]. Furthermore, MG-K10 will generate synergy with Dermavon's ruxolitinib cream (for mild to moderate AD), the oral small molecule TYK2 inhibitor CMS-D001 (for moderate to severe AD), and dermatology-grade skincare products of Heling soothing product series, establishing a comprehensive solution for AD that covers various administration routes (injection, oral, and topical) and addresses multiple needs in “treatment + care”, benefiting a wide range of AD patients. Concurrently, it will further enrich Dermavon's product portfolio in the field of dermatological treatment and reinforce its leading position in skin health sector.On 24 January 2025, CMS through its subsidiaries entered into a Collaboration Agreement (“Agreement”) with Hunan Mabgeek Biotech Co., LTD and its subsidiaries for MG-K10. In accordance with the Agreement and supplementary agreements, CMS has obtained the co-development rights (excluding AD) and exclusive commercialization rights for the Product in Mainland China, Hong Kong Special Administrative Region, Macao Special Administrative Region, Taiwan Region and Singapore; its subsidiary Dermavon has obtained, through its subsidiary, the co-development rights (excluding AD) and exclusive commercialization rights for the Product in the field of dermatological indications in Mainland China.About AD IndicationMG-K10’s first indication, AD, is a chronic inflammatory skin disease accompanied by severe itching. It is the most burdensome non-fatal skin disease worldwide and also a chronic disease with a relatively high prevalence and significant disease burden in China. It is estimated that there are over 54 million AD patients in China in 2024. Based on SCORAD scores, the proportion of moderate to severe AD in China was 27%, which means there are over 14.5 million patients[1]. Due to the limitations in efficacy and safety of traditional systemic therapies for AD, moderate to severe AD patients often experience delays in systemic treatment initiation, poor compliance, and suboptimal disease control, leaving a significant unmet need in clinical practice[2]. MG-K10, with its extended dosing interval of once every four weeks, is expected to improve patient adherence and provide a new, effective, and safe systemic treatment option for patients with moderate-to-severe AD.About CMSCMS is a platform company linking pharmaceutical innovation and commercialization with strong product lifecycle management capability, dedicated to providing competitive products and services to meet unmet medical needs.CMS focuses on the global first-in-class (FIC) and best-in-class (BIC) innovative products, and efficiently promotes the clinical research, development and commercialization of innovative products, enabling the continuous transformation of scientific research into clinical practices to benefit patients.CMS deeply engages in several specialty therapeutic fields, and has developed proven commercialization capabilities, extensive networks and expert resources, resulting in leading academic and market positions for its major marketed products. CMS continues to promote the in-depth development in its advantageous specialty fields, strengthening the competitiveness of the cardio-cerebrovascular/ gastroenterology/ ophthalmology/ skin health businesses, bringing economies of scale in specialty fields. Among them, the skin health business (Dermavon) has become a leading enterprise in its field, and is proposed to be listed independently on the SEHK. Meanwhile, CMS continuously promotes the operation and development of its integrated R&D, manufacturing and commercialization chain in Southeast Asia and the Middle East, capturing growth opportunities in emerging markets to support the high-quality and sustainable development  of the Group.Reference:1. China Insights Consultancy. Industry report on global and China Dermatology Treatment and Care Industry2. Chinese Society of Dermatology, China Dermatologist Association. Clinical pathway for the diagnosis and treatment of moderate to severe atopic dermatitis in China (2023): an expert consensus[J]. Chinese Journal of Dermatology, 2023, 56(11): 1000-1007. DOI: 10.35541/cjd.20230247.CMS Disclaimer and Forward-Looking StatementsThis press release is not intended to promote any products to you and is not for advertising purposes. This press release does not recommend any drugs, medical devices and/or indications. If you want to know more about the diagnosis and treatment of specific diseases, please follow the opinions or guidance of your doctor or other medical and health professionals. Any treatment-related decisions made by healthcare professionals should be based on the patient’s specific circumstances and in accordance with the drug package insert.This press release which has been prepared by CMS does not constitute any offer or invitation to purchase or subscribe for any securities, and shall not form the basis for or be relied on in connection with any contract or binding commitment whatsoever. This press release has been prepared by CMS based on information and data which it considers reliable, but CMS makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this press release. Certain matters discussed in this press release may contain statements regarding the Group’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. Any forward-looking statements and projections made by third parties included in this press release are not adopted by the Group and the Company is not responsible for such third-party statements and projections.Media ContactBrand: China Medical System Holdings Ltd.Contact: CMS Investor RelationsEmail: ir@cms.net.cnWebsite: https://web.cms.net.cn/en/home/ Copyright 2025 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

香港, 2025年10月30日 - (亞太商訊 via SeaPRwire.com) - 毅盛⾦融科技 (⾹港) 有限公司 (下稱「Esperanza」或「集團」)今日舉行「Esperanza 推動代幣化經濟新里程發佈會」 (「發佈會」)。為把握香港特區政府《2025施政報告》支持開發代幣化黃金投資產品的政策機遇，是次發佈會匯聚行業領袖及合作夥伴，共同擘畫香港發展代幣化黃金的戰略藍圖，探討其合規實踐與廣泛應用場景，並展望代幣化投資驅動亞太經濟增長的無限潛力，吸引近百位投資者及專業人士等參與。發佈會由Esperanza創辦人兼集團行政總裁梁衞晉律師發表的願景演講揭開序幕。梁衞晉律師指出，亞太區域經濟長久以來依賴西方結算系統和西方主導的利率政策，以代幣化黃金為基礎而發展的代幣化經濟為區內帶來另一選擇，有利中國內地與香港金融業持續國際化，同時為區內實體經濟發展帶來全新的資本方案。他強調，香港政府是次於2025年施政報告中提及支持發展代幣化黃金，為極具戰略思考的政策方向。香港憑藉國際金融中心的地位與資源，應積極發展以實體黃金為價值錨定的代幣化黃金，目標成為亞太區域實質經濟發展與跨境經貿的領導者。同時，未來代幣化黃金可以接壤央行主導的數字人民幣，為人民幣國際化出一分力。他亦介紹了Esperanza的創立背景、跨地域團隊及其核心理念，指集團現階段已完成向香港海關註冊為貴金屬支持工具發行方，並已完成概念驗證，其平台亦於多個亞太市場，包括東南亞、澳洲、日本、韓國等進行小範圍非公開測試，現有相當數量已完成「認識你的客戶 (KYC)」的實名制測試用戶。雖然Esperanza的代幣化黃金是根據香港海關註冊的貴金屬支持工具法律基礎設計，但為了香港的整體監管穩定性，預計在釋除其他監管機構的疑慮，並於香港完全實施明確監管框架後，Esperanza將開放代幣化黃金予香港公眾參與及通過戰略夥伴和各經濟體政府層面對接。梁衞晉律師續指：「代幣化黃金是香港金融未來的關鍵里程碑。集團團隊於施政報告前已經與亦辰集團有限公司 (8365.HK) 簽訂發展代幣化黃金事宜，並於施政報告發表後即時與特首政策組進行富有成效的深度交流，同時確保自身的技術平台與基建全面就緒。現階段，我們與監管機構保持積極對話，核心原則是於合規框架下實現『可控的創新』，並積極配合特首政策組的工作時間表。我們深信，Esperanza將憑藉技術與商業模式的先行優勢，協同各界，將代幣化黃金轉化為驅動亞太經濟自主的強大引擎。」發佈會共設兩場主題分享，首先由Esperanza 代幣化黃金業務董事總經理雷劍烽先生分享代幣化黃金的合規實踐路徑。雷劍烽先生指出，集團介紹的代幣化黃金實踐框架「ESPE Gold」(「ESPG」)，法律定位為「貴金屬支持工具」，而非虛擬資產、穩定幣或集體投資計劃。Esperanza透過購入符合倫敦金銀市場協會 (LBMA) 標準的實體金條，存放於持牌金庫，並以每公斤金條為基礎，對應發行十萬份ESPG數字證書。這些證書均記錄於不可篡改的區塊鏈上，每份代表一期分期支付的完成。當客戶累積完成十萬期支付後，即可向Esperanza兌換實體金條。此外，客戶亦可隨時進行分期支付或向集團出售ESPG，實現相較於傳統供金會的高度靈活性。他強調，此模式雖提供與穩定幣相仿的用戶體驗，但實際更類似傳統黃金商，依靠買賣價差獲取穩定收益。他亦講解ESPG的多元應用場景，除實體黃金投資與跨境支付結算外，未來更可在現實法規下探索抵押借貸等創新模式，致力構建完善的黃金利息體系。Esperanza 資本市場業務執行董事張仲宇先生於另一場主題分享介紹代幣化投資的佈局。張仲宇先生剖析，過往代幣化投資未能突破，關鍵在於缺乏具吸引力的產品設計，且流動性過度集中於專業投資者。要取得成功，關鍵在於構建兼具「未來成長預期」與「投資退出安全」的產品，例如短期具備收入增長潛力的收入分成投資模式。他續指，Esperanza已獲得證監會資產管理牌照，其代幣化業務申請正在審批中，並已完成相關法律、稅務及交易系統等基礎設施建設。目前，集團擁有的代幣化投資包括東南亞及韓國藝人演唱會收入分成，電影票房收入分成以及酒店未來收入分成等具吸引力的項目。除了一系列主題分享，發佈會更邀請到來自新加坡的Esperanza 聯合創辦人兼董事會成員趙治森先生，聯同梁衞晉律師及張仲宇先生，於圓桌討論環節以多方專業視角深入探討代幣化黃金與代幣化投資在亞太各經濟體的發展潛力。討論聚焦於Esperanza商業模式的獨特性、如何將東南亞項目引入香港進行證券型代幣發行 (Security Token Offering, STO) 融資，以及香港在特區政府支持下主導代幣化黃金發展的優勢與時機。是次發佈會標誌著Esperanza在香港乃至亞洲推動代幣化經濟發展的重要一步。展望未來，集團將繼續通過創新的金融科技解決方案，助力香港鞏固國際金融中心地位，並推動亞太地區實現更高水平的經濟自主與金融創新。圖片說明圖1：(由左至右) Esperanza 資本市場業務執行董事張仲宇先生、Esperanza創辦人兼集團行政總裁梁衞晉律師，以及Esperanza 代幣化黃金業務董事總經理雷劍烽先生，於發佈會上合照。 圖2：(由左至右) Esperanza 聯合創辦人兼董事會成員趙治森先生、Esperanza創辦人兼集團行政總裁梁衞晉律師，以及Esperanza 資本市場業務執行董事張仲宇先生，於圓桌討論環節後合照。關於毅盛⾦融科技 (⾹港) 有限公司 (Esperanza)Esperanza由香港及新加坡專業人士共同創立，是一家運用金融科技推動亞洲經濟改革的公司。Esperanza利用其代幣化黃金基礎建設及周邊金融配套，致力連繫亞洲經濟體，為區內實體經濟發展帶來全新的資本方案，鞏固香港的亞洲國際金融中心地位。未來預計通過將代幣化黃金對接亞洲各區央行數字貨幣，打造全球首個代幣化黃金廣泛應用經濟體，全面改革亞洲對西方金融結算系統及貸款利率的依賴。Esperanza採取低調、高效及果斷的商業模式營運。自2025年起短時間內已取得營運代幣化黃金的貴金屬交易商註冊登記、代幣託管所需的信託或公司服務提供者牌照，以及營運代幣化投資所需的資產管理受規管活動牌照。2025年8月，Esperanza與亦辰集團簽署代幣化黃金及化幣投資的合作協議，而同年9月香港政府將發展代幣化黃金納入施政報告。Esperanza的代幣化黃金及代幣化投資繼續沿用香港反洗錢及反逃税措施及規管要求，以金融科技大幅調低融資及營運成本，將產品直接與最終用戶對接。Esperanza代幣化金融系統將全力配合國家經濟走向國際化，致力成為國際結算及貿易系統替代方案。如欲瞭解詳情，請瀏覽Esperanza網站：espetopia.com Copyright 2025 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

HONG KONG, Oct 30, 2025 - (ACN Newswire via SeaPRwire.com) – Esperanza Fintech (Hong Kong) Limited (“Esperanza” or the “Group”) today hosted the “Conference: Implementation of Tokenized Economy by Esperanza” (“Conference”). It is an opportune moment as the Hong Kong SAR Government vows in her 2025 Policy Address to support the development of tokenized gold investment products. The Conference brought together industry leaders and partners to map out a strategic blueprint to implement tokenized economy, including the compliant roadmap for tokenized gold in Hong Kong and the unlimited potential of tokenized investments, an application for tokenized gold, in driving economic growth in the Asia-Pacific region. The Conference was attended by nearly a hundred investors and professionals.The Conference kicked off with a vision speech delivered by Mr. Ronald Leung, solicitor, Founder and Group CEO of Esperanza. Mr. Leung pointed out that the Asia-Pacific region has long relied on Western settlement systems and Western-dominated interest rate policies. The tokenized economy, powered by tokenized gold, offers an alternative capital solution to drive regional economic development and the continuous internationalization of the financial and capital markets of the Chinese Mainland  and Hong Kong . He emphasized that the support for development of tokenized gold in Hong Kong’s 2025 Policy Address is a highly strategic policy direction. Capitalizing on her status and resources as an international financial center, Hong Kong possesses unparalleled edge in developing an ecosystem powered by tokenized gold in facilitating cross-border trades in the Asia-Pacific region. Furthermore, tokenized gold could be integrated with Central Bank-led digital Renminbi (RMB) in the future to contribute to the internationalization of RMB. He pointed out that the Group has completed registration with the Hong Kong Customs as an issuer of precious asset-backed instrument. The Group has also undergone a small-scale, non-public proof-of-concept (POC) testing in multiple Asia Pacific markets, including Southeast Asia, Australia, Japan, South Korea, and currently has significant verified “Know Your Customer (KYC)” POC users. Although Esperanza's tokenized gold is designed based on the legal framework for precious asset-backed instrument registered with Hong Kong Customs, to ensure overall regulatory stability in Hong Kong, it is anticipated that Esperanza will open its tokenized gold offerings to the Hong Kong public only after addressing the concerns of other regulatory bodies and when a clear regulatory framework is fully implemented in the city. The Group will also align with governments of various economies on operational fronts via strategic partners.Mr. Leung continued to point out, "Tokenized gold is a key milestone for Hong Kong's financial future. Esperanza has already signed an agreement with Hatcher Group Limited (8365.HK) regarding the development of tokenized gold before the Policy Address was released. Immediately following the release, our team has conducted a productive and in-depth communication with the Chief Executive's Policy Unit, while ensuring our technology platform and infrastructure are in place and ready for action. Currently, we are maintaining active dialogues with regulators, with the core principle of achieving ‘controllable innovation’ that adheres to existing regulatory framework as well as the work agenda of the Chief Executive’s Policy Unit. We firmly believe that Esperanza, armed with first-mover advantages in technology and its business model, and in collaboration with various sectors, will be able to transform tokenized gold into a powerful engine in driving economic autonomy in the Asia-Pacific region."The conference had two thematic sharing sessions. The first had Mr. Roy Lui, Managing Director of ESPE Gold Solutions, sharing the compliant implementation of tokenized gold in Hong Kong. Mr. Lui shared that the Group’s proposed solution – “ESPE Gold” (“ESPG”) – is legally categorized as a “precious asset-backed instrument” instead of a virtual asset or a stablecoin, nor a collective investment scheme. Esperanza purchases physical gold bars adhering to London Bullion Market Association (LBMA) standards, stores them in licensed gold vaults and issues 100,000 ESPG, i.e. digital gold certificates, for each kilogram of gold bar. These digital gold certificates, each representing a complete instalment payment, are recorded on blockchain networks. Upon completion of 100,000 instalments, i.e. holding 100,000 ESPG, clients can redeem physical gold bars from Esperanza. Clients can make instalment payments any time and sell ESPG back to Esperanza, enjoying much higher flexibility than traditional gold redemption clubs. Mr. Lui emphasized that, although ESPG gives users experiences similar to that of stablecoins, the business model is actually more akin to traditional gold dealers earning bid-ask spread. He also spoke on the diverse application scenarios of ESPG besides as a convenient way to purchase physical gold. ESPG is poised to develop into a cross-border settlement means for commerce across Asia economies, with future potential to power a gold-backed interest rate system through collateralized lending of ESPG.In the second sharing session, Mr. Tony Chang, Executive Director of ESPE Capital Solutions, talked about the Group’s blueprint for tokenized investments as a core use case for tokenized gold. Mr. Chang said tokenized investments have not seen significant breakthrough due to the lack of product designs that are attractive to investors and that liquidity is highly concentrated within professional investors. Tokenized investments need to deliver both “attractive growth potential” and “security in exit channels” in order for investors to make meaningful consideration for adoption. Such example includes a short-term revenue sharing arrangement with foreseeable potential for revenue improvement. He added that Esperanza has obtained the Asset Management licence from the Securities and Futures Commission (SFC) of Hong Kong and its application for tokenized business is currently under review, with the legal, tax, and trading infrastructures ready. Currently, the Group’s tokenized investment pipelines include concert revenue of Southeast Asian and Korean artists, movie box office receipts and revenue of hotels and shopping malls.In addition to the thematic sharing sessions, the conference also featured a panel discussion comprising Mr. Jeremy Teo from Singapore, Co-founder and Board Director of Esperanza, Mr. Ronald Leung and Mr. Tony Chang. The discussion centers on the development potential of tokenized gold and tokenized investments across various Asia-Pacific economies, particularly the opportunities in bringing Southeast Asian projects to Hong Kong for capital raising via security token offerings (STOs). These opportunities illustrate the advantages for Hong Kong in developing tokenized gold with the support of the Hong Kong SAR Government.The conference marked an important step made by Esperanza in promoting the development of tokenized economy in Hong Kong and across Asia. Looking ahead, the Group will continue to provide innovative fintech solutions to support Hong Kong in strengthening her position as an international financial center, as well as helping foster greater economic autonomy and financial innovation in the Asia-Pacific region.Photo captionsPhoto 1: (From left to right) Mr. Tony Chang, Executive Director of ESPE Capital Solutions, and Mr. Ronald Leung, Founder and Group CEO of Esperanza, and Mr. Roy Lui, Managing Director of ESPE Gold Solutions, at the conference.Photo 2: (From left to right) Mr. Jeremy Teo, Co-founder and Board Director of Esperanza, Mr. Ronald Leung, Founder and Group CEO of Esperanza, and Mr. Tony Chang, Executive Director of ESPE Capital Solutions, after the panel discussion session.About Esperanza Fintech (Hong Kong) Limited (Esperanza)Esperanza is co-founded by the next generation of professionals from Hong Kong and Singapore with the mission to reform Asia’s economies through fintech. Esperanza is building the world’s first digital economy powered by a compliant tokenized gold infrastructure and its applications in finance. Esperanza aspires to reconnect Asia’s economies and integrate with their respective Central Bank Digital Currencies (CBDCs) to build autonomy against reliance on Western settlement systems and interest rate policies.Esperanza operates on a low-profile, highly efficient, and decisive business model. Since commencement in 2025, Esperanza has secured the registration as a Precious Metals and Stones Dealer (DPMS) with Hong Kong Customers and the Trust or Company Service Provider (TCSP) licence for the operations and custody of tokenized gold, and the Asset Management licence with the Securities and Futures Commission (SFC) of Hong Kong for the development of tokenized investments.In August 2025, Esperanza entered into a partnership agreement with Hatcher Group (8365.HK) relating to tokenized gold and tokenized investments. In September 2025, Hong Kong government has included the development of tokenized gold into its 2025 Policy Address.Esperanza's tokenized gold and tokenized investments continue to adhere to Hong Kong's Anti-Money Laundering (AML) requirements and common reporting standard for counter-tax evasion measures. Fintech solutions have enabled Esperanza to significantly reduce financing and operational costs, connecting products directly with end users. Esperanza’s tokenized finance system will fully support the globalization of national economy and is committed to becoming an alternative solution for international trades and settlements.To find out more, please visit the Esperanza website: espetopia.com Copyright 2025 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

深圳 , 2025年10月30日 - (亞太商訊 via SeaPRwire.com) - 康哲藥業控股有限公司（「康哲藥業」）欣然宣佈，旗下德鎂醫藥有限公司（「德鎂醫藥」，專業聚焦皮膚健康的創新型醫藥企業，正申請於香港聯合交易所有限公司主板獨立上市，詳見康哲藥業2025年4月22日發佈的公告）連同其附屬公司擁有共同開發權（除特應性皮炎（AD）外）和獨家商業化權利的1類新藥抗IL-4Rα MG-K10人源化單抗注射液（「MG-K10」或「產品」）中國上市許可申請（「NDA」）於2025年10月30日獲得中國國家藥品監督管理局（NMPA）受理。產品擬用於治療外用藥控制不佳或不適用外用藥治療的成人中重度特應性皮炎。MG-K10（通用名為柯美奇拜單抗注射液）是一種創新的長效抗IL-4Rα人源化單抗，能同時阻斷關鍵2型炎症因子IL-4和IL-13的信號傳導。憑藉更長的半衰期，產品可實現4週一次的給藥頻率（已上市抗IL-4Rα藥物均為2週一次給藥頻率），提升患者依從性，並有望成為全球首個上市的長效抗IL-4Rα單抗，具有成為同類最優（Best-in-Class）的潛力。MG-K10已在成人中重度AD的一項隨機、雙盲、安慰劑對照III期臨床研究取得陽性結果，達到方案設計的臨床試驗主要研究終點，且MG-K10治療52週時，研究者整體評估（IGA）評分達到0或1分，且較基線改善≥2分的受試者比例為 76.6%；達到濕疹面積及嚴重程度指數評分較基線至少改善75%（EASI 75）的受試者比例為94.3%；達到濕疹面積及嚴重程度指數評分較基線至少改善90%（EASI 90）的受試者比例為79.1%。安全性方面，治療期不良事件（TEAE）大多數為1-2級，未發生特別關注不良事件（AESI），未發生導致死亡的不良事件。同靶點藥物常見的不良反應（結膜炎、注射部位反應等）MG-K10發生率較低。產品有潛力用於治療其他2型炎症性疾病，如哮喘、結節性癢疹、季節性過敏性鼻炎、慢性阻塞性肺疾病、慢性自發性蕁麻疹、慢性鼻竇炎伴鼻息肉及嗜酸性粒細胞性食管炎等。其中，哮喘、結節性癢疹和季節性過敏性鼻炎均已進入中國III期臨床試驗階段。若該產品獲批上市，將為超1,450萬中重度AD患者[1]帶來新的有效且安全的系統治療選擇。同時，MG-K10將與德鎂醫藥的磷酸蘆可替尼乳膏（輕中度AD）、口服小分子TYK2抑制劑CMS-D001（中重度AD），及皮膚學級護膚品禾零舒緩系列形成協同效應，構建覆蓋注射、口服與外用等多種給藥途徑，兼顧「治療+護理」多重需求的AD綜合解決方案，惠及廣大特應性皮炎患者；並將進一步豐富德鎂醫藥皮膚治療領域的產品矩陣，鞏固其在皮膚健康領域的領先地位。於2025年1月24日，康哲藥業通過其附屬公司與湖南麥濟生物技術股份有限公司及其附屬公司就MG-K10簽訂合作協議（「協議」）。根據該協議及補充約定，康哲藥業獲得了產品在中國大陸、香港特別行政區、澳門特別行政區、臺灣地區及新加坡的共同開發權（除AD外）及獨家商業化權利；其中旗下德鎂醫藥通過其附屬公司獲得該產品在皮膚科適應症領域於中國大陸的共同開發權（除AD外）及獨家商業化權利。關於AD適應症MG-K10的首發適應症AD是一種伴有劇烈瘙癢的慢性炎症性皮膚病，是全球疾病負擔最高的非致命性皮膚病，同時也是我國患病率較高、疾病負擔較重的慢性疾病。據估算，2024年中國特應性皮炎患者超過5,400萬人，基於SCORAD評分，中重度特應性皮炎的佔比為27%，即超過1,450萬患者[1]。由於傳統AD系統治療藥物療效及安全性等方面的不足，在臨床中，中重度AD患者啟動系統治療往往較晚、依從性不佳、總體控制率較低，臨床上仍存在大量未被滿足的治療需求[2]。MG-K10給藥間隔更長，每4週給藥一次，有望提升患者依從性，給中重度AD患者帶來新的有效且安全的系統治療選擇。關於康哲藥業康哲藥業是一家鏈接醫藥創新與商業化，把控產品全生命週期管理的開放式平臺型企業，致力於提供有競爭力的產品和服務，滿足尚未滿足的醫療需求。康哲藥業專注於全球首創（FIC）及同類最優（BIC）的創新產品，並高效推進創新產品臨床研究開發和商業化進程，賦能科研成果向診療實踐的持續轉化，造福患者。康哲藥業聚焦專科領域，擁有被驗證的商業化能力，廣泛的管道覆蓋和多疾病領域專家資源，核心在售產品已獲領先的學術與市場地位。康哲藥業圍繞優勢專科領域不斷縱深發展，以鞏固心腦血管/消化/眼科/皮膚健康業務競爭力，帶來專科規模效率，其中皮膚健康業務（德鎂醫藥）已成為其細分領域的龍頭企業，並擬於聯交所獨立上市。同時，康哲藥業持續推動研產銷全產業鏈在東南亞及中東區域運營發展，以獲取新興市場的增量，助力集團實現高質量可持續發展。參考文獻/資料1. 灼識諮詢.《全球及中國皮膚科治療與護理行業研究報告》2. 中華醫學會皮膚性病學分會, 中國醫師協會皮膚科醫師分會. 中國中重度特應性皮炎診療臨床路徑專家共識（2023版）[J] . 中華皮膚科雜誌, 2023, 56(11) : 1000-1007. DOI: 10.35541/cjd.20230247.康哲藥業免責與前瞻性聲明本新聞無意向您做任何產品的推廣，非廣告用途。本新聞不對任何藥品和醫療器械和/或適應症作推薦。若您想瞭解具體疾病診療資訊，請遵從醫生或其他醫療衛生專業人士的意見或指導。醫療衛生專業人士作出的任何與治療有關的決定應根據患者的具體情況並遵照藥品說明書。由康哲藥業編制的此新聞不構成購買或認購任何證券的任何要約或邀請，不形成任何合約或任何其他約束性承諾的依據或加以依賴。本新聞由康哲藥業根據其認為可靠之資料及數據編制，但康哲藥業並無進行任何說明或保證、明述或暗示，或其他表述，對本新聞內容的真實性、準確性、完整性、公平性及合理性不應加以依賴。本新聞中討論的若干事宜可能包含涉及康哲藥業的市場機會及業務前景的陳述，該等陳述分別或統稱為前瞻性聲明。該等前瞻性聲明並非對未來表現的保證，存在已知及未知的風險、不明朗性及難以預知的假設。康哲藥業並不採納本新聞包含的第三方所做的任何前瞻性聲明及預測，康哲藥業對該等第三方聲明及預測不承擔責任。 Copyright 2025 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

香港, 2025年10月30日 - (亞太商訊 via SeaPRwire.com) - 冠君產業信託（「信託」）（股份代號：2778）在其九龍區旗艦物業朗豪坊辦公大樓49樓，擴充共享辦公空間Eaton Club，並在新址舉行開幕典禮。典禮期間同步舉辦「故事、策略與影響力：一場創辦人的對話」座談會。活動匯聚創新企業家、行業領袖及各界代表，共同見證 Eaton Club在九龍核心商業區的進一步擴展，並探討香港創業生態的未來發展。冠君產業信託表示，Eaton Club 是信託大生態圈（Ecosystem）中的重要成員，而朗豪坊辦公大樓正持續強化其作為大健康商業生態圈的核心樞紐角色，並逐步成為初創及創新企業在九龍市區的首選據點。全新擴充的49樓 Eaton Club 配備多元設施與多種辦公及活動場地，能夠充分滿足初創企業與多元職業者對共享辦公及活動空間的需求，並呼應政府支持創新企業引進與協助企業拓展國際市場的發展方向。升級後的 Eaton Club 創新地將健康理念融入共享辦公空間，不僅設有靈活的私人辦公室，更打造全新的 Social Wellness Hall，開放予業界夥伴舉辦各類健康主題活動及講座。此次空間擴充也與朗豪坊辦公大樓的「6 Dimensions Wellness Hub」發展方向緊密配合，共同構建一個促進企業與個人可持續發展的健康生態圈。是次開幕禮舉辦的座談會由香港投資推廣署初創企業部高級副總裁朱景泰先生（Mr. Kinder Chu）主持，並邀請三位本地傑出初創企業家分享經驗，包括：Beetales 創辦人江佩樺女士（Ms. Jill Kong）、Preface 創辦人及行政總裁盧炳棠先生（Mr. Tommie Lo），以及 The Loops Hong Kong 創辦人黃靖羲先生（Mr. Jorch Wong）。他們分別從環境保育、人工智能教育及可持續發展領域，探討香港新世代企業家面對的挑戰與機遇，並分享如何運用創新思維與策略推動業務成長。Eaton Club 總經理李少薇女士（Mimi Lee）表示：「是次座談會充分體現 Eaton Club 的核心理念— 匯聚人才、促進交流，成為推動香港商業發展的重要平台。隨著商業重心逐漸向非傳統金融區擴展，我們選擇在朗豪坊擴展，正是為了打造一個促進協同效應的樞紐，加強會員與集團寫字樓及商場租戶之間的聯繫，建立更強大的合作網絡。」Eaton Club自2016年成立以來持續擴展共享辦公空間網絡，隨著朗豪坊49樓全新空間投入使用，目前於中環、灣仔及旺角的總樓面面積已達八萬平方呎。新樓層特別增設多間一至二人辦公室，滿足初創及小型團隊需求。李少薇補充：「新空間亦設有可容納五十人的辦公方案，因為我們觀察到越來越多大型企業傾向採用彈性租約及一站式服務。會員同時享有地點靈活性，例如租用朗豪坊空間的會員亦可使用中環花園道三號的設施，包括我們自家營運的餐廳和活動場地。Eaton Club致力提供高效、便利及舒適的辦公環境，讓客戶更專注於業務發展。」有關冠君產業信託(股份代號：2778)冠君產業信託擁有及投資提供租金收入的寫字樓及零售物業。信託主要投資位於優越地點的甲級商用物業。現時擁有花園道三號及朗豪坊兩幢位於香港的地標性物業，並以合資股權形式擁有位於倫敦市中心的 66 Shoe Lane，總樓面面積約300萬平方呎，讓投資者可直接投資於優質甲級寫字樓及零售物業。信託自2023年榮獲全球房地產GRESB可持續的最高五星級別。冠君產業信託管理人乃鷹君資產管理（冠君）有限公司，為鷹君集團的成員。附件圖片1：Eaton Club朗豪坊49樓開幕典禮暨創辦人座談會圓滿舉行。左起：香港投資推廣署初創企業部高級副總裁朱景泰先生、The Loops Hong Kong創辦人黃靖羲先生、冠君產業信託行政總裁侯迅女士、Eaton Club總經理李少薇女士、Preface創辦人及行政總裁盧炳棠先生及Beetales創辦人江佩樺女士圖片2,3：Eaton Club 朗豪坊49樓的全新Social Wellness Hall，適合舉辦各類型活動及講座   圖片4,5：Eaton Club 朗豪坊49樓的共享辦公室，飽覽無敵景觀。圖片6,7 ：Eaton Club原有在朗豪坊5樓和48樓的共享辦公空間。媒體查詢：蘇杭財經劉旭霞 電話：+852 95066017 電郵：ada.lau@jervoisfinance.com Copyright 2025 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

HONG KONG, Oct 30, 2025 - (ACN Newswire via SeaPRwire.com) – Everest Medicines (HKEX:1952.HK) today announced that it has acquired an exclusive license with Visara, Inc. (“Visara”), a subsidiary of NovaBridge Biosciences (formally known as I-Mab, and is a company listed on the Nasdaq Global Market trading under the symbol “NBP”), to secure an exclusive license to develop, manufacture and commercialize VIS-101, in Greater China, Singapore, South Korea and certain Southeast Asian countries.This collaboration marks Everest’s strategic expansion into ophthalmology, a high-potential “blue-ocean” therapeutic area, further enriching its late-stage product pipeline and strengthening synergies across its core therapeutic portfolio.Under the assigned exclusive license, Everest Medicines will make an upfront payment of US$7 million (equivalent to approximately RMB49.7 million) and reimburse up to RMB24.0 million for prior expenses; and pay up to US$89.0 million (equivalent to approximately RMB632.0 million) in potential milestones; plus tied royalties on net sales.“We are pleased to collaborate with Visara. This partnership brings a highly differentiated and commercially attractive asset to Everest’s late-stage product pipeline and marks our entry into ophthalmology, a competitively attractive therapeutic area with significant unmet medical needs,” said Rogers Yongqing Luo, Chief Executive Officer of Everest Medicines. “Leveraging Everest’s clinical development and commercialization expertise, we look forward to advancing VIS-101, a potential best-in-class bifunctional antibody, towards commercialization in China and across Asia.”VIS-101 is a novel bifunctional biologic targeting VEGF-A and ANG-2 that is more potent and could potentially provide more durable treatment benefits than existing treatments for patients with wet age-related macular degeneration, diabetic macular edema, and retinal vein occlusion. VIS-101 has completed initial safety and dose-escalation studies in both the United State of America and China, and is currently completing a randomized, dose-ranging Phase 2 study in China. VIS-101 is anticipated to be Phase 3-ready in 2026.“VIS-101 is anticipated to be second-in-class with best-in-class potential, based on bioengineered, superior target neutralizing capabilities.” said Dr. Emmett T. Cunningham, Jr, Co-Founder and Executive Chairman of Visara.Globally, the market size for anti-VEGF ophthalmic drugs reached approximately USD 23 billion in 2024 and is projected to exceed USD 40 billion by 2030. In China alone, the prevalent patient population of AMD and DME exceeds 15 million, with around 600,000 new cases each year, yet only about 500,000 patients currently receive treatment. This indicates vast market potential.Visara is a subsidiary of NovaBridge Biosciences (Nasdaq: NBP), of which Everest Medicines is currently the largest shareholder. “Licensing out Greater China, South Korea and Southeast Asia rights to Everest Medicines is an important step toward streamlining global commercial rights and creating synergy in global clinical development,” said Dr. Sean Fu, Chief Executive Officer of NovaBridge Biosciences. “We are excited to work with Everest Medicines team as a strategic partner."Under its “dual-engine” strategy, Everest Medicines has established a commercialization platform anchored by two blockbuster products targeting high-potential markets and powered by the in-house in vivo CAR-T and mRNA therapeutic cancer vaccine platforms. The Company will continue to focus on key therapeutic areas and new growth markets, with ophthalmology as the next growth driver to strengthen synergy across its core portfolio.Everest’s core product pipeline in rental diseases, infectious diseases, and autoimmune disorders has entered a critical growth stage. NEFECON® and XERAVA® have established sustainable commercial cash flow generation, while VELSIPITY® (etrasimod) is expected to become the company’s next blockbuster product. Everest continues to enhance its innovation capability and long-term competitiveness by leveraging its industry-leading mRNA therapeutic cancer vaccine platform and mRNA in vivo CAR-T platform.At a recent corporate strategy meeting, Everest Medicines announced plans to in-license more than three high-potential assets within the next 6–12 months, with an aggregate domestic peak sales potential exceeding RMB10 billion. Combined with its existing portfolio, Everest Medicines expects its total domestic peak sales potential to surpass RMB20 billion. Copyright 2025 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

香港, 2025年10月30日 - (亞太商訊 via SeaPRwire.com) - 10月30日，雲頂新耀宣布已與Visara簽訂協議，獲得獨家許可，在大中華區、新加坡、韓國及若干東南亞國家進行臨床開發、生產和商業化VIS-101。該合作標志著雲頂新耀正式進軍眼科這一高潛力藍海領域，豐富了公司的後期產品管線，進一步拓展其核心治療領域佈局。根據指定獨家許可，雲頂新耀將支付700萬美元（相當於約人民幣4,970萬元）的預付款，及不超過人民幣2,400萬元的自付費用報銷；最高不超過8,900萬美元（相當於約人民幣6.32億元）的潛在開發及銷售里程碑款項；以及按淨銷售額的潛在特許權使用費。雲頂新耀首席執行官羅永慶先生表示：「我們非常高興與Visara建立合作夥伴關系，此次戰略合作引入的創新藥物VIS-101兼具高度差異化與商業潛力，進一步豐富了公司的後期產品管線，並將業務拓展至眼科這一臨床需求尚未充分滿足且具有創新機會的藍海治療領域，為公司發展注入新的增長動能。未來，我們將依托公司卓越的臨床開發能力和商業化平台，高效推進VIS-101這一潛在同類最佳的雙功能生物制劑在中國及亞洲地區的臨床開發與商業化進程，盡快為患者提供這一創新治療選擇。」VIS-101是一款新型雙功能生物制劑，針對VEGF-A與ANG-2，其療效較第一代治療更為顯著，可有望為濕性年齡相關性黃斑部病變（wet AMD）、糖尿病性黃斑部水腫（DME）及視網膜靜脈阻塞（RVO）患者提供更持久的治療效益。VIS-101已於美國及中國完成初步安全性與劑量遞增研究，目前正於中國進行隨機分組的劑量範圍II期臨床試驗，預計將於2026年具備進入III期臨床試驗的條件。Visara聯合創始人兼執行主席Cunningham博士表示：「VIS-101有望成為該類別中第二款上市的藥物，並具備同類最佳（best-in-class）的潛力。這源於其在生物工程上的優異設計，使其具備更強的靶點中和能力。」目前，抗VEGF（血管內皮生長因子）療法是眼底疾病的主要治療手段，通過抑制眼內異常新生血管的生成與滲漏，從而改善視功能。2024年全球抗VEGF眼科藥物市場規模已達約230億美元，預計到2030年將超過400億美元。眼科藥物市場空間廣闊，僅在中國，wet AMD和DME的現有及新增患者人數已超過1,500萬，每年新增約60萬例，而目前接受抗VEGF治療的患者人數僅約50萬，存在巨大的未被滿足的臨床需求。Visara為新橋生物（前稱為I-Mab，納斯達克股票代碼：NBP）的附屬公司，雲頂新耀目前是新橋生物的第一大股東。新橋生物首席執行官傅希湧博士表示：「此次將VIS-101大中華區、韓國及東南亞地區的權益授權給雲頂新耀，是我們在優化全球商業佈局、推動全球臨床開發協同方面邁出的重要一步。我們期待與雲頂新耀共同推進該產品在亞洲地區的戰略協作，為更多患者帶來創新治療選擇。」此次合作是雲頂新耀在「雙輪驅動」戰略指導下的又一關鍵落子。公司正在構建以多個大單品商業化平台為基石、以自體生成CAR-T平台與mRNA腫瘤治療性疫苗平台的自主研發與臨床轉化為引擎的價值體系。未來，公司將持續聚焦優勢治療領域，引進高潛產品，進一步強化核心產品組合的協同效應。目前，雲頂新耀在腎科、感染及自身免疫性疾病等核心治療領域的產品管線已進入關鍵收獲期。耐賦康(R)與依嘉(R)已形成可持續的商業化造血能力，維適平(R)（艾曲莫德）有望成為下一個確定性大單品。在自主研發方面，公司依托領先的mRNA腫瘤治療性疫苗平台與自體生成CAR-T平台為核心，持續夯實自研技術壁壘。在近期的發展戰略交流會上，公司進一步明確未來6-12個月計劃引進3個以上的重磅產品，預計引進產品的潛在國內銷售峰值將超過人民幣100億元，疊加現有產品矩陣，整體國內銷售峰值有望突破人民幣200億元。 Copyright 2025 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

香港, 2025年10月30日 - (亞太商訊 via SeaPRwire.com) - 專注於中國健康飲食行業的透雲生物科技集團有限公司（「透雲生物」，連同其附屬公司統稱「集團」；股份代號：1332.HK）欣然宣佈，集團旗下全資子公司山西透雲生物科技有限公司近日與中國健康產品領域知名渠道商多家核心夥伴，包括深圳樓宇間供應鏈科技股份有限公司、河南國字頭營銷管理有限公司及北京合萬家生物科技有限公司，組成之銷售聯合體正式簽署戰略合作協議。根據戰略合作協議，2026年至2028年底，上述銷售聯合體將向透雲生物採購總金額不少於人民幣10億元之萊茵衣藻系列產品。此標誌性合作不僅為集團萊茵衣藻業務奠定量級放大之商業基礎，亦宣示相關產品線已由區域性試點階段邁向全國化、結構化鋪排與放量，進一步夯實透雲生物於中國健康膳食、功能營養與綠色食品原料賽道的產業領先地位。本次採購協議的正式落地，標誌著透雲生物的萊茵衣藻及微藻產品已由研發驗證與先導試用階段，全面邁入可規模交付的商業化新階段 — 即具備工業化、標準化、可持續、可追溯之穩定供應能力。是次協議屬量級採購安排，亦即對產能、品質一致性、合規體系、供應鏈韌性及交付節奏的全方位驗證。對集團而言，這不僅是一筆訂單，更是一個產業拐點 — 萊茵衣藻正由「創新食材」走向「行業標配」。此里程碑進一步鞏固集團「新一代綠色蛋白與功能營養供應商」之市場定位。透雲生物不再只是提供單一原料，而是輸出一整套可複製的營養解決方案 — 涵蓋低GI配方、高蛋白/全胺基酸譜設計、富微量元素強化方案、以及針對不同消費人群（控糖人群、體重管理人群、三高風險人群、銀髮族等）的功能型膳食應用模組。集團預期，是次合作將在放量、場景擴展與C端滲透三個層面產生牽引效應：i) 推動其萊茵衣藻業務由區域性試點銷售走向全國性鋪排，實現生產端與銷售端的同步擴容與規模經濟；ii) 加速微藻原料進入更多日常高頻品類，包括健康主食、便利即食、功能代餐、餐飲定制菜單、營養加強型小食等，使其從「創新亮點」變為「常規標配」；及iii) 以B端（餐飲、渠道、大健康企業）作為推進樞紐，帶動消費端對藻基營養的認知與接受度，構建「微藻＝健康」的普遍心智，為品牌後續直接面向消費者的零售型產品鋪墊基礎。集團相信，隨著是次協議所對應的採購需求逐步兌現，透雲生物將能為健康主食、控糖控脂膳食方案、功能型即食／速食產品、代餐營養品等快速增長的細分市場，提供可持續、可標準化、可長期追溯的高規格原料底座，從而在中國「健康膳食產業升級」的進程中佔據更具戰略性的供應端主導位置。透雲生物董事會主席兼執行董事王亮先生表示：「當前，消費者對健康飲食的理解已不再局限於傳統的『少油少鹽』，而是進一步聚焦於『高營養、可持續、具功能訴求』。本次簽訂人民幣10億元的戰略採購協議，乃市場對透雲生物於工業化量產能力、品質一致性、標準化交付能力以及研發迭代速度的系統性肯定。展望未來，集團將繼續強化供應鏈韌性，在保障食品安全與品質穩定的前提下，有序擴大產能，進一步完善原料端、配方端、應用端的全鏈條能力。集團會持續輸出標準化、模組化、低GI及富微量元素的整體營養解決方案，協助合作夥伴升級其核心產品線，並推動萊茵衣藻走入更廣泛的民生場景，最終讓高營養、低碳足跡的綠色食品真正普及到千家萬戶。透雲生物的戰略定位，是成為中國健康主食與功能餐飲領域的養生原料標準制定者與長期供應者，並以中國為起點，逐步走向全球。」關於透雲生物科技集團有限公司透雲生物科技集團有限公司（股份代號：1332.HK）主要從事萊茵衣藻產品業務、包裝產品設計、研發、生產及銷售業務，同時亦為向中國快速消費品提供產品包裝上的二維碼以及商務智慧資訊技術解決方案的市場領導者。集團紮根傳統包裝業務超過三十載，在香港以及廣東多地設有辦公室及製造車間，目前為眾多世界知名品牌提供專業包裝設計及製造服務，擁有長期穩定的客戶群。自2020年起，集團多元化發展業務範圍至萊茵衣藻、微藻產品業務，並與山西省長治市潞城區人民政府合作建設全球首座萊茵衣藻工廠，以展開萊茵衣藻工業化量產。如欲查詢更多資料，請瀏覽集團網站：https://touyunbiotech.com.hk/zh-hant/  Copyright 2025 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

TOKYO, Japan – October 30, 2025 - (ACN Newswire via SeaPRwire.com) - The Northeast Asia Video Summit 2025, hosted by the Asia Video Industry Association (AVIA), brought together leading media executives, content creators, and technology innovators to explore the future of video in Japan and Korea. Held in Tokyo, the summit showcased transformative strategies in global content production, streaming monetization, and cross-border collaboration.A central theme of the summit was the global ascent of Japanese and Korean content. In a compelling keynote, Katsuaki Setoguchi, Executive Officer at TBS Holdings and President and CEO of THE SEVEN Inc., emphasized that Japan’s ambition to go global is rooted not in profit, but in cultural promotion. “Storytelling is our foundation,” Setoguchi said, highlighting the success of Alice in Borderland and upcoming co-productions with U-Next. He outlined a formula for global success: strategic IP selection, elevated production budgets, and partnerships with platforms like Netflix and Amazon to reach a global audience. Setoguchi also stressed the importance of long-term regional collaboration, particularly in Southeast Asia, citing their strategic alliance with Vietnam TV.Yu Sasamoto, CEO of DAZN Japan and APAC Business Development, shared insights into Japan’s evolving sports streaming landscape. With partnerships like Docomo and Meta, DAZN is redefining how fans engage with live sports. Sasamoto revealed that DAZN is set to triple its subscriber base in Japan and is leveraging social media to convert engagement into subscriptions. Sasamoto also shared his ambitions to expand Japanese sports globally by building an ecosystem that blends content, technology, and partnerships to scale across Asia.Streaming monetization was another hot topic. Joshua Sunghyun Cho, CBO of TVING, detailed the platform’s innovative ad strategies, including impression-guaranteed products and interactive formats like “Watch Together.” Partnering with Moloco, TVING doubled its ad revenue from KBO baseball broadcasts and is now targeting contextual and shopping ads. “Streaming is no longer just premium branding—it’s performance-driven,” Cho said. Nick Chuah, Managing Director APAC at INVIDI, added that addressable advertising is poised to reshape Japan’s TV ad market, with data-driven campaigns delivering measurable ROI and unlocking new value for brands.Executives from Dentsu, FAST Corporation, and Integral Ad Science also echoed the need for collaboration, standardization, and advocacy to accelerate CTV adoption in Japan. With new smart TVs and platforms like TVer and ABEMA entering the programmatic space, the market is poised for rapid growth.The summit also addressed the future of anime as a global cultural force. Yuichiro Saito, CEO of Studio CHIZU, and Hideki Henry Goto, President of OKUTAGON LLC, discussed anime’s expanding international footprint. With over half of revenue now coming from global markets, speakers called for new business models, international co-productions, and talent development to sustain growth, with Saito advocating for creative integrity and global collaboration.In the closing keynote, executives from Warner Bros. Discovery, SKY Perfect JSAT, and A+E Global Media debated the future of pay TV and streaming economics in Japan. While acknowledging the slow decline of linear TV, they emphasized the enduring value of local partnerships and bundling strategies. Japan’s rich history and vibrant culture continue to produce compelling stories, presenting vast opportunities for international partnerships to bring this content to global audiences. The speakers agreed that creative distribution models and co-productions will be key to unlocking Japan’s full potential on the global stage.The Northeast Asia Video Summit is proudly sponsored by Gold Sponsors Moloco and Publica by IAS, and Silver Sponsors Encompass, INVIDI and TV5MONDE.Click here for a selection of photos from the Summit.About the Asia Video Industry AssociationThe Asia Video Industry Association (AVIA) is the trade association for the video industry and ecosystem in Asia Pacific. It serves to make the video industry stronger and healthier through promoting the common interests of its members. AVIA is the interlocutor for the industry with governments across the region, leads the fight against video piracy through its Coalition Against Piracy (CAP) and provides insight into the video industry through reports and conferences aimed to support a vibrant video industry.For media enquiries and additional background information, please contact:Charmaine KwanHead of Marketing and CommunicationsEmail: charmaine@avia.org | Website: www.avia.orgLinkedIn: www.linkedin.com/company/asiavideoia |X: @AsiaVideoIA  Copyright 2025 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

Placement of 20,000,000 Placement Shares at S$0.39 each has been fully taken up, raising gross proceeds of S$7.8 million.Prominent institutional funds and investors that subscribed for the Placement Shares include Lion Global Investors Limited (as investment manager for and on behalf of its clients), Asdew Acquisitions Pte Ltd, ICH Synergrowth Fund, Ginko-AGT Global Growth Fund and Mr Tan Kim Seng, among others.Supported by Singapore’s robust construction outlook of S$39 billion to S$46 billion annually from 2026 to 2029 and large-scale coastal protection initiatives of S$100 billion, the Group is well-positioned to capitalise on growth opportunities with its integrated and synergistic business model.SAC Capital Private Limited acted as the Placement Agent in relation to the Placement. Maybank Securities Pte. Ltd. acted as the Placement Agent and the Sub-Placement Agent.Singapore, Oct 29, 2025 - (ACN Newswire via SeaPRwire.com) - SGX-Catalist listed Reclaims Global Limited (“Reclaims Global” or the “Company” and together with its subsidiary, the “Group”), an eco-friendly integrated service provider within Singapore’s construction sector, is pleased to announce that the Company has successfully completed a share placement (“Placement”), comprising a total of 20,000,000 new shares issued at a price of S$0.39 per share, raising gross proceeds of S$7.8 million.With its integrated and synergistic business model within Singapore’s construction industry, the Group specialises in the customisation of excavation/demolition/building construction solutions, operating fleet management of construction vehicles and equipment as well as the recycling of construction and demolition waste.“This successful placement marks a key milestone for the Group as the macro growth momentum in Singapore’s construction industry, coupled with national investment in coastal protection initiatives, creates opportunities for Reclaims Global to deliver enhanced long-term value to our stakeholders,” said Mr. Chan Chew Leh, Executive Chairman.“Building on our established foundation and track record within the construction industry, Reclaims Global is well-positioned to pursue larger-scale projects as a trusted partner. Backed by strong sectoral tailwinds, we aim to expand our market presence and capture new business opportunities via our integrated and synergistic business model,” added Mr. Tan Kok Huat, Executive Director and Chief Executive Officer.In its latest 1H2026 results (for the financial year ended 31 July 2025) announced on 9 September 2025, Reclaims Global reported revenue growth of 14.9% to S$21.78 million (as compared to previous corresponding period) with net profit of S$2.5 million. The Company has announced an interim dividend of S$0.005 per share for 1H2026 and over the past two years, the Company has paid at least S$0.01 per share of dividends annually.About Reclaims Global Limited(SGX - NEX / Bloomberg - RGL: SP/ Reuters - RECL.SI)Listed on the Catalist of the SGX-ST in March 2019, Reclaims Global Limited is an eco-friendly integrated service provider within Singapore’s construction industry, specialising in the customisation of excavation/demolition/building construction solutions, operating fleet management of construction vehicles and equipment as well as the recycling of construction and demolition waste.The Group’s integrated and synergistic business model is organised into three main business segments as follows: (1) excavation services; (2) logistics and leasing; and (3) recycling.Since its inception in 2009, the Group has established a strong reputation and proven track record for reliable execution and timely delivery of diverse projects across the construction sector.For more information, please refer to the corporate website https://reclaims-enterprise.comIssued on behalf of Reclaims Global Limited by 8PR Asia Pte Ltd.Media & Investor Contacts:Mr. Alex TANMobile: +65 9451 5252Email: alex.tan@8prasia.com   Copyright 2025 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

香港, 2025年10月30日 - (亞太商訊 via SeaPRwire.com) - 10月27日，中國新能源汽車行業中的頭部企業——賽力斯集團股份有限公司（「賽力斯」，股份代號：9927）正式啟動招股，赴港上市更進一步，此次上市若順利完成，公司有望成為港股市場首家實現「A+H」兩地上市的豪華新能源車企。問界M9豐富產品矩陣 市場表現亮眼作為一家以新能源汽車為核心業務的技術科技型企業，賽力斯業務版圖全面覆蓋新能源汽車及核心三電等產品的研發、製造、銷售及服務。公司旗下高端品牌「問界」精准聚焦豪華細分市場，憑藉清晰的產品定位、出色的綜合性能及豪華的屬性，在行業內收穫高度認可，被業內人士譽為「中國的奔馳寶馬」。而從科技維度出發，問界在品牌「智慧重塑豪華」理念的推動下，展現出「豪華+科技」雙軌並行的獨特定位。在定義未來科技出行方面，如輔助駕駛、智能安全、智能動力等，问界又與特斯拉秉持高度一致的願景。截至目前，問界系列車型的輔助駕駛功能累計行駛里程已突破34.5億公里，輔助駕駛行駛里程占總里程比例40%，輔助駕駛功能成績亮眼。與此同時，賽力斯在科技創新與前沿科技持續探索，積極佈局具身智能領域，近期公司已正式宣佈與火山引擎達成合作，共同推進具身智能的研發與應用創新，顯示出與國際領先車企不謀而合的戰略前瞻性。在科技領域的成績與探索也使得問界品牌被業內人士譽為「中國的特斯拉」。揆諸實際，無論是問界在豪華細分市場的深耕與精准定位，還是當下輔助駕駛等科技成果的穩健落地，正是對「智慧重塑豪華」品牌理念的深度踐行。這一理念精准契合用戶對智慧與豪華並重的核心訴求，讓用戶無需在豪華質感與智能體驗間作出取捨，既避免了在單一維度發展的局限，更讓「豪華 + 科技」的雙重價值真正轉化為用戶可感知的日常使用體驗。在產品端，問界品牌已構建起覆蓋問界M9、問界M8、問界M7、問界M5的完整產品矩陣，實現對高端市場的全面滲透，市場表現持續亮眼，旗下主力車型長期領跑細分市場，2024年問界M9穩居50萬級高端SUV銷量冠軍，問界M8在2025年4月正式上市後僅24小時大定即突破3萬。根據Frost & Sullivan報告，問界品牌在2024年下半年以82%的NPS淨推薦值登頂新能源汽車口碑榜首，且2024年問界品牌全年總交付量達38.71萬輛，同比增長268%，充分印證了其在高端新能源汽車市場的核心競爭力。問界全系列強化研發投入與技術創新 業績增長強勁在夯實產品矩陣、鞏固市場份額的同時，賽力斯持續深耕技術創新領域，以高強度研發投入築牢發展根基。於2022年、2023年、2024年以及2025年上半年，公司研發開支分別達人民幣1,313.7百萬元、人民幣1,696.5百萬元、人民幣5,585.5百萬元及人民幣2,929.5百萬元，呈現顯著增長態勢。從研發費用占收入比重來看，各期分別為3.9%、4.7%、3.8%及4.7%，彰顯出公司對技術創新的高度重視。領先的核心技術能力，是賽力斯的產品持續實現功能創新、獲得市場成功的重要驅動力之一。公司自主打造的魔方技術平臺，通過平臺化造車模式，有效降低了整車開發成本，同時大幅提升開發的敏捷性和靈活性。該平臺憑藉全景安全、多元動力、百變空間、智慧引領四大核心優勢，為用戶提供了「好開、好用、超安全」的智能用車體驗。同時，作為首家商業化量產增程器的自主整車企業，賽力斯持續引領新能源車增程技術的發展，將增程技術從「可用」進化到「好用」，並在油電轉換率和NVH性能兩項關鍵指標上獲得國家權威認證機構的認可，其最新發佈的全新一代超級增程系統油電轉換效率達到3.65kWh/L，處於行業量產增程器的最高水平。此外，賽力斯始終將產品安全視為底線，圍繞車輛全生命週期，構建了涵蓋被動安全、主動安全等九大維度的智能安全體系。目前，公司開發了81項碰撞場景，搭載該體系的問界M9榮獲C-NCAP、C-IASI國內兩大測評指數雙第一的優異成績。在ESG治理與可持續發展領域中，賽力斯也取得亮眼成績，2025年10月16日，根據國際權威指數公司明晟(MSCI) 公佈最新企業ESG評級結果，賽力斯集團獲得最高AAA評級，成為唯一獲此評級的A股上市汽車企業，彰顯賽力斯集團在構建未來出行生態中的引領力量。值得一提的是，公司通過融合創新的方式與合作夥伴共同打造了先進的智能座艙和輔助駕駛功能，並通過深度融合整車控制技術，從整車跨域協同維度持續優化輔助駕駛體驗，為用戶提供更加智能、便捷的駕駛感受。財務表現上，賽力斯近年業績增長勢頭強勁，盈利成果顯著。2023年至2024年，公司收入從人民幣358億元躍升至1451億元，同比大幅增長305.5%；公司毛利率同步提升，從2023年的7.2%穩步增至2025年上半年的26.5%，盈利空間持續拓寬。盈利層面，公司於2024年、2025年上半年分別錄得歸母淨利潤人民幣59億元、人民幣29億元，成功實現盈利突破。根據Frost & Sullivan報告，公司是全球第四家實現盈利的新能源車企，財務健康度與行業競爭力凸顯。總體而言，賽力斯憑藉清晰的高端產品佈局、領先的技術創新與穩健的盈利增長，已在新能源汽車賽道建立起穩固的行業地位。此次擬赴港上市，既是對其過往發展成果的認可，更將為其深化技術研發、拓展全球市場注入新動能，有望在全球汽車產業變革中持續領跑，為中國自主品牌車企高質量發展寫下新的注腳。 Copyright 2025 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

香港, 2025年10月30日 - (亞太商訊 via SeaPRwire.com) - 10月27日，中國新能源汽車行業頭部企業—賽力斯（股份代號：9927）啟動招股，目前招股正在進行中，即將叩開港股市場大門，有望成為首家A+H豪華新能源車企。極具競爭力的產品體系在產品層面，賽力斯憑藉深厚的技術積澱與精准的市場定位，構建起極具競爭力的產品體系。其中，公司於2021年重磅發佈的高端品牌「問界」，截至目前，問界品牌已成功推出問界M5、問界M7、問界M8及問界M9四款核心產品，累計服務用戶已突破80萬。更值得關注的是，公司旗下主力車型長期穩居細分市場頭部陣營，問界M9持續領跑高端SUV賽道，穩居50萬級市場銷量冠軍。問界M8始終穩居40萬級市場榜首，成為高端用戶的首選之一。問界M9憑藉「雙旗艦」車型的亮眼表現與強大品牌影響力，賽力斯被業界高度認可，贏得了「中國的奔馳寶馬」這一重磅讚譽，彰顯出公司在高端新能源汽車市場的領軍地位。在定義輔助駕駛、智能安全、智能動力等未來出行領域，賽力斯與特斯拉秉持高度一致的願景。截至目前，問界系列車型的輔助駕駛功能累計行駛里程已突破34.5億公里，在該領域，僅特斯拉與問界穩居前兩位，疊加賽力斯在具身智能與科技創新領域的持續深耕與積極探索，赛力斯被行業廣泛視作「中國的特斯拉」。問界對豪華市場的深耕定位與輔助駕駛等科技成果的落地，既是 “智慧重塑豪華” 理念的深度實踐，也精准匹配用戶對智慧與豪華兼具的需求，跳出單一維度發展局限，讓 “豪華 + 科技” 價值成為用戶可感知的體驗。全方位的技術創新實力在技術層面，賽力斯持續推動技術創新，逐步確立行業競爭優勢並打造堅實的技術壁壘。公司自主研發的魔方技術平台，是具備持續進化能力的智能平台，也是行業內首個兼容增程、純電與混動三種新能源動力總成的平台，其模塊化設計使公司能夠高效、可靠地實現系列車型的快速量產。目前，賽力斯最新一代超級增程系統已實現量產，熱效率高達44.8%，油電轉化率達到3.65kWh/L，處於行業領先水平。 魔方技術平台在用戶安全方面，賽力斯以全場景安全需求為驅動，全面構建覆蓋被動安全、主動安全等九大維度的安全體系，涵蓋超過180項用戶用車場景，開發出300余項安全功能，打造全方位的安全防護能力。此外，賽力斯還構建了端雲一體化的測試平台，其自研的智能測試終端可實現測試車輛7×24小時不間斷的自動化測試。通過自動化測試技術，公司構建了覆蓋研發、生產、供應、銷售全流程的質量自動化攔截體系，全面保障產品質量。賽力斯在 ESG 治理與可持續發展領域同樣成效顯著，2025 年 10 月 16 日拿下國際權威機構明晟（MSCI）最高 AAA 評級，作為 A 股上市車企中唯一獲此評級的企業，其未來出行生態引領地位得以凸顯。財務方面，賽力斯近年來實現跨越式增長，業績表現尤為亮眼。2024年營業收入突破1451億元，同比增長305.5%，實現歸母淨利潤59億元，成功實現歷史性扭虧為盈，2025年上半年，公司延續盈利向好態勢，實現淨利潤29億元，展現出強勁增長勢頭。賽力斯以產品力、技術壁壘與安全體系築牢發展根基，憑亮眼財務數據印證強勁實力。若此次赴港上市順利落地，其將正式開啟「A+H」雙資本平台驅動模式，未來有望持續領跑高端新能源賽道，書寫行業發展新篇章。 Copyright 2025 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com